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CHAPTER 1: INTRODUCTION
1.1 Protein quality control in the endoplasmic reticulum
At its most basic level, cellular life is dependent on the progression of genetic
information being converted from DNA into RNA and culminating into proteins. Due to
intrinsic mechanisms dedicated to ensuring the accuracy of genomic replication,
prokaryotic and eukaryotic error rates are lower than 1x10-8 and 1x10-10 respectively [1].
The chance of error increases significantly during transcription (1x10-4 per codon in
prokaryotes [2]) and translation (1x10-3-4 in prokaryotes [1, 3]). Additionally, the fidelity of
protein folding in the endoplasmic reticulum (ER) can be low due to the crowded nature
of molecular activity where the protein concentration can reach as high as 300 mg/mL
[4]. Simple proteins can fold quickly with relative ease (estimated around 50 ms [4]),
whereas other, more complex protein complexes can take hours to reach their native
conformation [4]. Evolutionary advancements in cellular machinery have allowed cells to
complete their tasks, such as protein synthesis, with greater efficiency; however, this
may involve sacrificing the proper maturation of proteins for a faster overall mechanism,
yielding more product. To combat this, the cell has developed quality control systems to
help remove proteins that are not properly folded, and in the ER specifically, ERassociated degradation (ERAD) is devoted to safeguarding the maturation of secretory
and endocytic proteins.
1.1.1 The degradation of ER proteins - a history
For many years, the lysosomal pathway, through a process known as autophagy,
was thought to handle the removal of anomalous or unused secretory and endocytic
proteins [5]. This was the assumption due to formation of lysosomes from vesicles in the
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Golgi apparatus and their trafficking through the secretory pathway, and the similar
route travelled by proteins that failed quality control tests [6-8].
The dogma of how secretory proteins were degraded began to change after
experiments were performed examining the question if proteins are degraded prior to
reaching the lysosome and if the ER played a role in the quality check of secreted
proteins. Using T-cell receptor subunit α (TCRα), it was demonstrated that this protein
was indeed degraded prior to reaching the Golgi and was independent of the lysosome
[9, 10]. A few years after these initial reports, it was discovered in yeast that the E2
ubiquitin-conjugating enzyme UBC6 mediated the degradation of some proteins in the
ER. In this case, the presence of UBC6 null mutants prevented the removal of mutant
Sec61 (a component of the ER translocon) from the ER [11]. Further evidence showed
the stabilization of ER protein substrates via proteasome inhibition in human cells and in
yeast [12]. Together, these data helped change the lysosomal-dependent theory of
secretory protein degradation to the idea that misfolded proteins are removed from the
ER, transported into the cytosol, and degraded by the proteasome.
1.1.2 Substrate misfolding
!

Despite complex molecular machinery in place to ensure the proper maturation of

polypeptides that enter the ER, protein misfolding is inevitable. To ensure that misfolded
proteins do not accumulate, anomalous proteins are degraded as they are recognized.
In ERAD, misfolded proteins are recognized, ubiquitinated and extracted into the cytosol
to be degraded by the proteasome [13].
"

Cells are under constant stress associated with the accumulation of misfolded

proteins. It is estimated that around one-third of the polypeptides that enter the ER are
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degraded [14]. Misfolding can occur through a variety of errors in transcription or
translation, or simply from genetic mutations in the protein itself, including premature
stop codons in the amino acid sequence and point mutations in the DNA. For example,
two different mutations in the protease inhibitor alpha-1 antitrypsin (A1AT) prevent the
protein from folding correctly and thus result in its degradation [15]. Similarly, a
phenylalanine deletion at position 508 on the cystic fibrosis transmembrane
conductance regulator (CFTR) protein causes disease and is degraded once
recognized by quality control mechanisms [16]. In addition, damage to proteins via heat,
chemical modifications or oxidative stress can all prevent a protein from reaching its
native conformation and subjects the protein to degradation by the proteasome [17].
1.1.3 Polypeptide detachment from ribosome
!

The ER is a membrane-bound organelle that is continuous with the nuclear

envelope, and proteins bound for endocytic or secretory fate are folded here following
translocation from the ribosome (Figure 1) [18, 19]. Translocation of polypeptides from
the ribosome generally occurs via the Sec61 protein channel and is done cotranslationally, meaning that some protein folding is happening concomitant with peptide
synthesis [20, 21]. A hydrophobic tag, known as the N-terminal signal sequence, aids in
the targeting of membrane and soluble proteins and is recognized by the signal
recognition particle which directs proteins to the ER in eukaryotes [21-23]. The signal
sequence is not included in the maturation of proteins because it is cleaved from the
protein by a signal peptidase once inside the ER [23].
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FIGURE 1: PROTEIN FOLDING IN THE ENDOPLASMIC RETICULUM
Cellular Membrane
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FIGURE 1: Secretory and endocytic proteins folded in the endoplasmic reticulum (ER)
are first synthesized by ribosomes. The growing polypeptide is imported into the ER
and recognized by a variety of folding proteins. Properly folded secretory proteins are
exported out of the ER and to the Golgi before being sent to their final destination.
Conversely, improperly folded proteins are recognized in the ER and are integrated
into a protein quality control mechanism termed ER-associated degradation (ERAD).
After being recognized as a misfolded protein, resident E3 ubiquitin ligases associated
with the ER will tag the misfolded protein with ubiquitin and the protein is exported out
of the ER and into the cytosol for its subsequent degradation by the 26S proteasome.
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1.1.4 Chaperone-assisted protein folding
!

Because some polypeptides fold inside the lumen of the ER, there must be

machinery in place to ensure that the hydrophobic regions do not aggregate together.
Chaperones are molecules essential for nearly every aspect of protein quality control as
they prevent protein aggregation and help proteins reach their native conformations
[24]. Chaperones can belong to any one of several families; arguably the best known
chaperones belong to the heat shock protein (Hsp) subfamily, named according to their
molecular weight ranging from 40-100 kDa [25].
"

Belonging to the Hsp70 subfamily of chaperones, Grp78/BiP is one of the first

chaperones to interact with nascent polypeptides entering the ER [26]. Grp78/BiP was
found to bind with peptides that contain alternating hydrophobic and aromatic residues
[27]. Because this is a common sequence found in proteins (it is estimated that most
proteins contain a hydrophobic interacting region once every 36 residues), Grp78/BiP
can interact with a wide range of substrates and nearly completely cover the length of
the protein [28]. The consistent binding of Grp78/BiP to nascent polypeptides upon
entering the ER helps ensure the polypeptides move “forward” in their maturation and
do not progress backwards into the cytosol [29].
1.1.5 Asparagine (N)-linked glycan-assisted protein folding
!

Besides the innate advantages of glycan-protein association (e.g. mediating

interactions between cells by covering the surface of mammalian cells), N-linked
glycans are important players in the molecular recruitment and maturation of proteins in
the ER [30, 31]. It is estimated that more than 50% of proteins in eukaryotes are
glycosylated and 1% of all genes in mammals are dedicated to glycosylation [32-34].
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This process is believed to help fold and stabilize the maturing protein, as well as
increase the protein’s solubility [35].
"

In this process, the asparagine-linked glycan moiety is transferred to the

glycosylation sequence of a protein (asparagine-X-serine/threonine; the X amino acid
cannot be proline due to nucleophilic requirements of the reaction [36]) by the
oligosaccharyltransferase (OST) membrane complex. Best studied in yeast, OST is
composed of eight subunits: Ost1p, Ost2p, Ost3p/Ost6p, Ost4p, Ost5p, Swp1, Stt3p,
and Wbp1 [37]. All of these subunits in yeast have mammalian homologs, with the
exceptions of Ost5p and Ost4p [38, 39]. In mammals, five subunits are assumed to form
the core of OST: DAD1, OST48, ribophorin I and II, and STT3A/STT3B [40]. There are a
minimum of two separate binding sites in the OST complex [41], and it is responsible for
the generation of the Glc3Man9GlcNAc2 species on the polypeptide [42]. Overall, this
glycan network in the ER helps maintain the reliability of protein production and folding
after release from the ribosome.
1.1.6 Regulation of protein folding by calnexin/calreticulin
!

Calnexin, and its paralog calreticulin, are crucial regulators of glycoprotein folding.

These chaperones recognize specific glycan moieties produced by the cleavage of
glucose residues via glucosidase I/II [43-45]. Importantly, calnexin and calreticulin
recruit proteins important for catalyzing disulfide bond formation [46-48] as well as
proteins that mediate calnexin/calreticulin binding to polypeptides allowing time for
folding to occur in order to help retain proteins in the ER [31].
"

Calnexin/calreticulin serve as a quality checkpoint in the protein folding process.

When glucosidase II removes the final glucose molecule after the glycan is released by
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calnexin, the protein is allowed to continue through the secretory pathway if it is
correctly folded [49]. Conversely, if a protein has failed to reach its native conformation it
can be given another chance to fold correctly, or will be removed from the ER [49]. The
soluble protein UDP-glucose:glycoprotein glucosyltransferase recognizes improperly or
incompletely folded proteins, and tags the protein to enter the calnexin/calreticulin cycle
again [50].
1.1.7 Selecting proteins to traverse the ER membrane
!

New polypeptides are released from ribosomes at a constant pace. Thus, it is

critical that the ER maintains homeostasis within the organelle by removing the proteins
that are misfolded or unable to fold. Intuitively, a protein repeating the folding process
over and over creates an overflow of nascent proteins and not enough secreted, native
proteins. Cleaving the terminal mannose off glycan moieties prevents the polypeptide
from trying to refold, and generally serves as the signal for proteins to be removed from
the ER and degraded by the proteasome [51-53].
"

The export of misfolded proteins out of the ER has been a hotly contested topic in

the field of protein folding and quality control for many years. A few theories have
emerged that a protein channel is the likely mode of protein export into the cytosol,
however the proteins that make up this channel are unknown. One potential candidate
is the Sec61 translocon, which is primarily responsible for mediating the transport of
proteins into the ER [54, 55]. Different groups have shown that Sec61 physically
interacts with substrates in the ER [54, 56, 57]. Expressing mutant Sec61 protein in
yeast causes an accumulation of protein substrates in the ER [58] or disrupts the
degradation of misfolded proteins in the ER [59]. Despite these data, the crystal
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structure of the prokaryotic SecY translocon (homologous to Sec61) demonstrates the
channel takes the shape of two funnels with the narrow stems facing each other which
may only be large enough to fit unfolded, extended polypeptides [55, 60], conflicting
with the potential role of Sec61 as an import and export channel.
"

Derlin1 (Der1 in yeast), a four-transmembrane domain protein exposes a small

region into the cytoplasm [61] and is potentially another candidate that functions to
export anomalous proteins out of the ER [62, 63]. When der1 is deleted in yeast, ER
lumenal protein turnover is absent; however, membrane-bound ER proteins are largely
unaffected [64, 65]. Mammalian Derlin1 can form large protein complexes in the ER
membrane [62, 66], thus supporting the premise that this protein functions as a channel
exporting proteins out of the ER for proteasomal degradation. However, the evidence for
how proteins are ultimately extracted out of the ER via Sec61 or Derlin1 is still largely
controversial at best. Future studies in protein export after misfolding are needed to
make this process more clear.
1.2 Protein ubiquitination
The process of tagging proteins with ubiquitin is one of several post-translational
modifications that can occur, and is the primary method of signaling protein degradation
by the proteasome. Ubiquitination is a crucial regulator of most cellular pathways and
relies on several enzymes functioning in a coordinated series of steps (Figure 2). First,
as an energy dependent process, ATP is expended and free ubiquitin forms a highenergy intermediate with the catalytic cysteine of an E1 ubiquitin-activating enzyme [67].
After being transferred to an E2 ubiquitin-conjugating enzyme, ubiquitin attachment to a
protein substrate is mediated by an E3 ubiquitin ligase [67]. Ubiquitin is attached to a
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target protein as a single ubiquitin species or as a polyubiquitin chain conjugated to
itself via one of seven residues (K6, K11, K27, K29, K33, K48, K63), or as a linear chain
[68]. The fate of the protein typically depends on the type of polyubiquitin attached to it.
K48-linked chains target polypeptides for proteasomal degradation, whereas K63-linked
chains play functional roles in processes including DNA repair, signal transduction, and
trafficking [69-73]. In mammals, there are two E1s, dozens of E2s, and hundreds of
known E3 ubiquitin ligases [74, 75].
1.2.1 Ubiquitin-conjugating enzymes
As the name would suggest, E2 ubiquitin-conjugating enzymes play an important
role in the conjugation of ubiquitin to substrates. Members of the ubiquitin-conjugating
family share a conserved region, termed the ubiquitin-conjugating catalytic (UBC) fold,
which is responsible for providing binding regions for E1 and E3 proteins, as well as
activated ubiquitin [76, 77]. Well-characterized in yeast, ubiquitin-conjugating enzymes
are present in all eukaryotic systems, demonstrating the importance of ubiquitin
biological systems [78, 79]. Throughout evolution the ubiquitin-conjugating family has
expanded where higher eukaryotes have more E2s than lower eukaryotes [79].
Comparatively, there are 50-75 known [68] human ubiquitin-conjugases compared to 16
characterized conjugases in yeast [79].
The degradation of proteins via ER quality control mechanisms in mammals (or
yeast) depends on the activity of various ubiquitin-conjugating enzymes: Ube2J2
(Ubc6), Ube2G2 (Ubc7), Ube2K (Ubc1), Ube2J1 (Ubc6e) [80-83]. Evidence regarding
structure and sequence similarities with orthologs demonstrates that Ube2G2 is highly
conserved and underlies its physiological importance in ubiquitination [84].
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FIGURE 2: PROCESS OF UBIQUITINATION
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FIGURE 2: The tagging of proteins with ubiquitin is one of several post-translational
modifications that can occur and is used commonly to label misfolded, toxic, or shortlived proteins with ubiquitin in order to signal for their proteasomal degradation in
eukaryotes. In an ATP-dependent manner, ubiquitin is transferred in a series of steps
from an E1 activating enzyme to an E2 ubiquitin-conjugase before interacting with an
E3 ubiquitin ligase. Substrates can be tagged with one ubiquitin moiety, or this
process can repeat itself several times, forming a polyubiquitin chain on the misfolded
protein. Monoubiquitination generally has non-proteolytic, signaling roles, whereas
polyubiquitinated substrates can be proteasomal substrates. This process can be
reversed by a set of proteases known as deubiquitinating enzymes, which can edit the
length of the polyubiquitin chain or completely remove the ubiquitin chain from the
protein.
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1.2.2 ER ubiquitin ligases in protein quality control
The final step of ubiquitination is carried out by a family of proteins known as E3
ubiquitin ligases. Two of the most commonly studied E3 ligase families are the RING
(really interesting new gene) and HECT (homologous to E6-AP carboxyl terminus)
ligases, which have different modes of action (Figure 3). For HECT ligases, ubiquitin is
transferred from the ubiquitin-conjugating enzyme to the ligase and lastly to the protein
substrate. On the other hand, RING ligases act similarly to a scaffold, ushering the
ubiquitin moiety from the E2 directly to the substrate [86]. RING ligases can function in
the cytosol (e.g. CHIP) or be membrane-bound entities (e.g. HRD1) [87, 88]. RING
ligases can function as single proteins or as a part of a larger complex. Parkin, a single
molecule ubiquitin ligase, contains a recognition motif and RING domain in itself [89].
Conversely, large ubiquitin ligase complexes have several different proteins that share
the roles of substrate recognition and RING domain catalytic activity, among other roles
[86].
In yeast, depending on the location of the misfolded substrate, one of two E3
RING ligases could be used; the Doa10 ligase complex removes anomalous proteins
from the cytosolic space, whereas the Hrd1p ligase functions in the ER lumen and
membrane [90, 91]. The lines for these distinct roles in yeast are blurred, but in humans
there does seem to be subtle specificity for ligase-substrate interaction. For example,
HRD1 in humans has been shown to associate with soluble and membrane-bound
proteins in the ER [92, 93].
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FIGURE 3: E3 UBIQUITIN LIGASES IN UBIQUITINATION
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FIGURE 3: The ubiquitination process has been described (Figure 2), and while the
roles of E1 activating enzymes remain fairly consistent (only two known E1 enzymes
in mammals), there are a variety of functions between E2 ubiquitin-conjugases and E3
ubiquitin ligases. There are two different types of E3 ubiquitin ligases: RING and
HECT ligases. There are hundreds of RING ligases compared to only dozens of
HECT ligases in mammals, and their roles in transferring ubiquitin to misfolded
substrates differ. For HECT family E3 ubiquitin ligases, ubiquitin is transferred from E1
to E2 to E3 in a sequential manner prior to labeling the substrate with the ubiquitin
moiety. Conversely, for RING family ubiquitin ligases, the E3 ligase acts as a
scaffolding protein, mediating the transfer of ubiquitin from the E2 ubiquitin-conjugase
to the substrate protein.
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In humans, HRD1 and GP78/AMFR are two of the better characterized E3 ligases
in the ER. Both ligases are homologous to the yeast Hrd1p, but each forms a different
complex and presumably targets different substrates [92, 94-97]. Various other E3
ligases have been implicated through mammalian systems in quality control, but the
exact function and roles of these ligases remains largely unclear; however they are
assumed to contribute to the turnover of a limited range of substrates compared to
HRD1 and GP78/AMFR [98-106]. Currently, some substrate/ligase preference has been
demonstrated, but delineating these interactions specifically has been a difficult task,
especially because the exact identifying features of the misfolded protein that are
recognized by ubiquitin ligases are chiefly unknown [107]. Interestingly, GP78 itself is a
substrate of HRD1 [108, 109]; therefore, decreased levels of HRD1 leads to increased
GP78 protein and increased turnover of GP78 specific substrates.
1.2.2.1 HMG-CoA reductase degradation protein 1 (HRD1)
HRD1 (also known as Synoviolin in mammals) is a 617 amino acid protein (Figure
4) which includes six transmembrane domains, a catalytic RING domain, and an
arginine-rich VCP/p97 binding domain near its C-terminus [110-113]. Due to its innate
role as a resident E3 ubiquitin ligase in the ER, HRD1 is responsible for essentially
targeting substrates for proteasomal degradation by tagging them with ubiquitin. HRD1
was first found to be implicated in the turnover of 3-hydroxy-3-methylglutaryl coenzyme
A reductase and is named as such [114].
HRD1 activity is induced via ER stress and is implicated in the etiology of
rheumatoid arthritis by protecting cells from apoptosis, leading to hyperplasia [115].
Besides HMGR and GP78, other reported substrates of HRD1 include misfolded insulin,
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FIGURE 4: HMG-CoA REDUCTASE DEGRADATION PROTEIN 1 (HRD1)
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FIGURE 4: (A) The 617 amino acid (a.a.) protein HRD1 belongs to the RING family of
ligases. HRD1 contains six transmembrane domains (TM; blue), a RING ligase region
necessary for its catalytic activity (green), and an arginine-rich VCP/p97 binding
domain (purple) important for mediating the interaction between HRD1 and VCP/p97.
Additionally, wild type HRD1 contains 4 lysine (K) residues in its non-membranebound region that we mutated into the non-ubiquitinatable amino acid arginine (R) for
experiments in this report. The red arrow labels amino acid 241, and an HRD1
construct containing amino acids 241 to 617 is used for several biochemical, in vitro
experiments omitting the membrane-bound portion of HRD1. (B) Detailed amino acid
sequence of HRD1 where the cytoplasmic domain used for in vitro experiments is
highlighted in red font. The catalytic cysteine residue in the RING domain is
highlighted in green, and the four lysine resides in the cytosolic region are shown in
blue. Also shown are the four arginine residues that compose the VCP/p97 binding
domain of HRD1.
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TCRα, and CD3δ [116-118]. The association of HRD1 with various lectins such as
XTP3-B and OS-9, as well as the derlin family of proteins and Sel1L (a protein
implicated in the degradation of glycoproteins), is found to form a large, membranebound complex that functions in ERAD [63, 119]. The HRD1 gene is essential in
mammals as mouse models have demonstrated that knockout mice are embryonic
lethal [120]. HRD1 has been shown to interact with at least two different ubiquitinconjugases: Ube2G2 and Ube2J1 [96, 118]. Despite this knowledge, the exact role(s) of
HRD1 in ERAD is not well understood.
1.2.3 Anomalous protein extraction from the ER
VCP/p97 (known as Cdc48 in yeast), is a AAA ATPase with several diverse roles,
but arguably best known for its role in ERAD [121-123]. Early work in yeast using
biochemistry and genetic manipulations found that Cdc48 functioned as a segregase,
separating ubiquitinated proteins from the membrane of the ER, as well as other
reported roles in mitotic spindle disassembly [124, 125].
In mammalian systems, VCP/p97, along with cofactors UFD1 and NPL4, bind
ubiquitin, thus implicating VCP/p97 in quality control mechanisms, more specifically
ERAD [126]. Proteins including Erasin, UBXD8, and VIMP function as recruitment
factors for VCP/p97 towards the location of the misfolded protein in the ER membrane
and interact with VCP/p97 through each protein’s UBX domain that resembles ubiquitin
structurally [62, 96, 127, 128]. Interestingly, mammalian HRD1 and GP78 both have
VCP/p97 binding motifs [110, 129]. By and large, VCP/p97 is thought to guide misfolded
substrates to the proteasome after ubiquitination of the substrate has occurred [130,
131].
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Some work has attempted to delineate the method by which anomalous proteins
are exported out of the ER. Cell studies have demonstrated that the removal of
polypeptides from the ER membrane is an ATP-driven process [132]. VCP/p97 is
composed of six subunits that assemble into a hexamer along with two ATPase
domains. It was noted that a conformational change is perhaps the step that allows
protein export to proceed from mechanical energy produced by the rotation of the
hexamer due to the hydrolysis of ATP [133, 134]. Altogether, mediating the extraction of
ubiquitinated proteins from the ER has been a well documented role of VCP/p97.
1.2.4 Proteasomal degradation of proteins
After the misfolded polypeptide has been recognized in the ER, ushered through
the ER lumen to the membrane, tagged for export out of the ER by ubiquitin, and
translocated into the cytosol, the last stage of ERAD is protein degradation by the
proteasome. The 26S proteasome is composed of a 20S catalytic core and one or two
19S cap particles [135]. Very putative “ubiquitin receptors” RPN10 and RPN13
recognize substrates in the cytosol that need to be degraded and there are a variety of
proteins inside the 19S proteasome cap that prepare the substrate to enter the 20S core
[136, 137]. A set of enzymes known as deubiquitinating enzymes (DUBs; will be
discussed further in section 1.3) can salvage ubiquitin moieties by removing the
polyubiquitin chain from the substrate to reuse. The substrate is unfolded into a
polypeptide stretch by ATPases and, once inside the 20S core of the proteasome, the
polypeptide is proteolytically degraded and released back into the cytosol as small
peptides that are subsequently cleaved into single amino acids by endo- or aminopeptidases [138].
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1.3 Deubiquitinating enzymes (DUBs) in protein quality control
The process of ubiquitination is reversible by a set of enzymes, known as DUBs,
that control the ubiquitin status of a protein by modifying the isopeptide bond between
molecules. DUBs function by editing the length of the polyubiquitin chain on the
substrate itself, or by completely removing the ubiquitin chain [139]. There are roughly
95 human DUBs encoded in the genome which are divided into five classes of
intracellular cysteine or metallo-proteases based on the topology of the catalytic domain
[140]. Ubiquitin specific proteases (USP; by far the largest family with over 50 proteins
in humans), Machado-Joseph disease proteases (MJD), ubiquitin C-terminal hydrolase
(UCH), and Otubain proteases (OTU) are all cysteine proteases (referring to the amino
acid used in their active site) and JAB1/MPN/Mov34 metallo-enzymes, as the name
suggests, are metallo-proteases where a conserved cysteine interacts with a zinc
residue in the active site. Increased understanding of the function and roles of DUBs
has led to several new implications of DUBs in diseases, including neurodegenerative
disease, infectious disease and malignancies [141, 142].
1.3.1 Deubiquitinating enzymes in ERAD
YOD1, a DUB in the Otubain protease class, was one of the first DUBs implicated
in ERAD and protein extraction from the ER [143]. In this report, Ernst and colleagues
hypothesized that in order for the ubiquitin-tagged protein to pass through the VCP/p97
channel, the polyubiquitin chains must be edited or removed. By expressing the inactive
form of YOD1, the export of proteins out of the ER is inhibited. Additionally, further work
demonstrated that the addition of a DUB from the Epstein-Barr virus blocked the
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degradation of ER proteins, resulting in the accumulation of proteins in the cytosol,
similar to what one would expect in cells by using proteasome inhibitors [144].
Other DUBs have been implicated in the secretory pathway and in ERAD. For
example, USP19 has been shown to remove ubiquitin moieties from the ERAD
substrates TCRα and CFTRΔF508, rescuing them from degradation by the proteasome
[145]. Conversely, inhibiting the function of the DUBs ataxin-3 or USP13 that function in
quality control results in the accumulation of misfolded ER substrates [146, 147].
Additionally, besides YOD1 as previously mentioned, VCP/p97 has been shown to
interact with a variety of DUBs in ERAD including ataxin-3, VCPIP1, and USP13
[146-148]. DUBs associated with VCP/p97 edit ubiquitin chain length of the substrate,
which has been shown to recycle the protein or conversely, improve proteasomal
targeting [126, 130]. Interestingly, ataxin-3 has been shown to interact with another
proteasomal shuttle protein, hHR23 (also known as Rad23) where the presumed
function is that ataxin-3 deubiquitinates and transfers the substrate to hHR23, while
keeping the polyubiquitin chain long enough to still be recognized by the proteasome for
degradation [146].
1.4 Endoplasmic Reticulum-Associated Degradation (ERAD)
As mentioned, proteins that fail to reach their native conformations in the ER
trigger a quality control mechanism known as endoplasmic reticulum-associated
degradation, or ERAD, to sort misfolded proteins out of the crowded ER and into the
cytosol for degradation by the proteasome. It does this in a series of four seemingly
simple steps: 1) chaperones in the ER will recognize the misfolded substrate
distinguishing it from nascent molecules; 2) an E3 ubiquitin ligase in the ER will tag the
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polypeptide with ubiquitin; 3) the ubiquitin-tagged protein will be exported out of the ER,
presumably through a protein channel; and, 4) the 26S proteasome will recognize the
substrate by the polyubiquitin tag and enzymatically degrade the protein, preventing a
toxic accumulation of immature proteins (Figure 5).
1.4.1 ER stress
When the capacity of the ER is reached, but new polypeptides are still being
imported into the ER for folding, this is deemed “ER stress” and is important because it
functions as a signaling system that the accumulation of misfolded, aggregated species
is imminent. The unfolded protein response (UPR) is the umbrella mechanism under
which ERAD functions and works to maintain cellular homeostasis in times of stress.
Three separate resident ER membrane proteins work as transducers of UPR signal and
are activated when BiP/Grp78 dissociates from the signaling peptides in the lumenal
region and binds to misfolded polypeptides: IRE1, PERK, and ATF6.
IRE1, the most conserved of the ER stress transducers, is found in all eukaryotic
species [149]. The cytosolic region of IRE1 contains endoribonuclease activity as well
as a serine/threonine kinase [150, 151]. The activation of IRE1 results in the
transcriptional activation of XBP1, a transcription factor responsible for regulating the
cellular expression of genes during stress [152]. In a similar manner, PERK activation
results in the translation of another transcription factor, ATF4, which promotes the
transcription of chaperones to help alleviate the stress [153]. Lastly, after dissociation
from BiP/Grp78, ATF6 leaves the ER and is exported to the Golgi where it is cleaved by
proteases in order to enter the nucleus, where it functions to upregulate proteins
involved in ERAD and protein folding [154].
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FIGURE 5: ENDOPLASMIC RETICULUM-ASSOCIATED DEGRADATION
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FIGURE 5: Endoplasmic reticulum-associated degradation (ERAD) is a protein quality
control process in the ER responsible for removing misfolded, short-lived, and toxic
proteins from the ER lumen. This prevents the toxic accumulation of proteins when
protein folding is taking place, decreasing the likelihood of disease due to inefficient
folding. ERAD functions in a series of four steps: 1) the misfolded substrate is
recognized by an E3 ubiquitin ligase in the ER (HRD1 in this scenario); 2) the E3
ubiquitin ligase will ubiquitinate the protein and a proteasomal shuttle protein (such as
VCP/p97) will recognize the ubiquitinated substrate; 3) the ubiquitin-tagged protein is
extracted into the cytosol and is 4) ushered to the proteasome to be enzymatically
degraded.
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1.4.2 ER stress and disease
It is becoming more generally accepted that cell and molecular injury due to
prolonged ER stress plays a major role in the pathophysiology of a variety of diseases,
notably, but not limited to, malignancies and neurodegeneration [155]. Despite most
human diseases being vastly different in the tissues they affect and their clinical
manifestation, many share a common molecular thread in which protein misfolding is at
the root of the disease etiology, or is a significant contributor at the very minimum. Some
of the diseases associated with ER stress are discussed below.
1.4.2.1 ER stress and malignancy
Tumor cells often invade cellular environments where metabolic or oxidative stress
conditions impedes the ER’s ability to properly fold proteins [156-159]. Studies have
identified a high ER stress response from the signal transducers in the ER in various
cancer types including breast, liver, esophageal, glioblastoma, multiple myeloma, and
gastrointestinal [160-165]. A fraction of solid tumors have been noted to have genetic
mutations in IRE1 [166], and many components necessary for efficient protein folding in
the ER (e.g. BiP) have been demonstrated to be upregulated to levels that correlate
with disease advancement [167, 168]. Despite knowing many proteins in ERAD are
implicated in disease progression, it is still unclear if they inhibit or enhance tumor
growth in humans. In vivo work in rodent models has demonstrated the role of ER
protein folding components in both pro- and anti-angiogenic scenarios, as well as
demonstrated the ability to stall or promote tumor cell growth [169-172].
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1.4.2.2 ER stress and neurodegeneration
A hallmark of a variety of neurological disorders is the accumulation of protein
aggregates affecting neurons and neighboring cells [173]. Notable examples of this
includes the accumulation of tau and amyloid β in Alzheimer’s disease or Lewy bodies
(ubiquitinated protein aggregations composed of α-synuclein) in Parkinson’s disease.
Not all neurodegenerative disorders share the same pathophysiology in regards to
protein aggregation. Others are the result of genetic mutations in disease proteins (as is
the case in Huntington’s disease (huntingtin)) which contain abnormally expanded
polyglutamine domains. Additionally, prions have been shown to form protein
aggregations and have been implicated in the encephalopathies kuru and CreutzfeldtJakob disease [174, 175]. The build-up of misfolded proteins is toxic to neurons [176],
and there is growing evidence that neuronal cell aging, oxidative stress, impaired
protein degradation and genetic mutations all contribute to protein aggregation and ER
stress, culminating in neurotoxicity and disease [177-179].
1.4.2.3 ER stress and other human diseases
Several studies have implicated ER stress with cardiovascular disease, notably
tissue injury from ischemia [180]. The restriction of blood vessels under ischemic
conditions causes hypoglycemia and hypoxia. Hypoxia and metabolic stressors cause
proteins to misfold and leads to subsequent ER stress. After restoration of normal blood
flow, oxidative stress in the ER from the ischemic event disturbs proper protein folding.
Activation of the UPR has also been demonstrated in rodent models and in humans in
the formation of atherosclerosis [181, 182]. Knowing this, it is not surprising that some
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evidence has documented the activation of ER stress in cases of high cholesterol and
high fatty acid content [183].
There are roughly one million predicted insulin molecules created every minute by
human pancreatic β-cells [184]. Due to the high amount of protein turnover, β-cells need
properly functioning ERs in order to keep glycemic states normal because an
abnormally low amount of produced insulin in the body causes diabetes. Insulin
resistance in obesity due to malfunctioning β-cells can lead to ER stress and may
induce type 2 diabetes [185]. Similarly, inflammation because of autoimmunity in type 1
diabetes causes the remaining β-cells to over-produce insulin [186]. These events
cause a vicious circle of consistently high ER stress levels, leading to diabetes.
1.5 Concluding remarks
Through a variety of biochemical, cellular, and genetic assays, many central
components of ERAD have been characterized and described. It is clear that ERAD is
essential for the regulation of many aspects of cellular biology including protein folding,
ubiquitin-dependent degradation, protein transport, and regulation of metabolism.
Pathogens attempt to exploit this system in order to disrupt cellular homeostasis and
cause disease. ERAD is an essential component of cellular biology and is a critical
moderator for the delicate balance between protein folding and protein degradation. It
was the goal of this project to understand how components of ERAD collaborate in
normal and disease states in order to yield different outcomes.
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CHAPTER 2: MATERIALS AND METHODS
2.1 Antibodies
The following primary antibodies were used for western blot analysis throughout
the course of this dissertation: rabbit, polyclonal anti-Ubiquitin (1:500; Dako; Carpinteria,
CA); rabbit, polyclonal anti-HRD1/SYVN1 (1:1,000; Sigma-Aldrich; St. Louis, MO);
rabbit, polyclonal anti-HA (Y11) (1:500; Santa Cruz; Dallas, TX); mouse, monoclonal
anti-V5 (1:5,000; Invitrogen; Carlsbad, CA); mouse, monoclonal anti-APP, clone 22c11
(1:1,000; EMD Millipore; Billerica, MA); rabbit, polyclonal anti-GFP (1:1,000; Santa Cruz;
Dallas, TX); rabbit, polyclonal USP25 (1:4,000; previously described [187, 188]); mouse,
monoclonal anti-c-Myc (9e10) (1:250; Santa Cruz; Dallas, TX); mouse, monoclonal antiUbe2J1 (1:500; Origene; Rockville, MD); rabbit, polyclonal anti-Ube2G2 (1:500;
Origene; Rockville, MD); rabbit, monoclonal anti-K48-linkage Specific Polyubiquitin
(1:1,000; Cell Signaling; Danvers, MA) [189]; rabbit, polyclonal anti-VCP (1:1,000; Cell
Signaling; Danvers, MA); rabbit, monoclonal anti-K63-linkage Specific Polyubiquitin
(1:1,000; Cell Signaling; Danvers, MA) [190]; mouse, monoclonal anti-GAPDH (1:500;
EMD Millipore; Billerica, MA); mouse, monoclonal anti-Tubulin (1:20,000; Sigma-Aldrich;
St. Louis, MO); mouse, monoclonal anti-KDEL (1:500; Enzo Life Sciences; Ann Arbor,
MI); mouse, monoclonal anti-E4B (1:500; BD Biosciences; San Jose, CA); rabbit,
polyclonal anti-GP78/AMFR (1:1,000; Cell Signaling; Danvers, MA). Peroxidaseconjugated mouse and rabbit secondary antibodies (Jackson Immunoresearch; West
Grove, PA) were used at 1:5,000 concentration.
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2.2 Biochemical in vitro reactions
Bacterial cultures using BL21 competent cells were used for recombinant protein
production as previously described [191-194]. Biochemical in vitro reaction procedures
have been described before [192, 193, 195]. Briefly, 1X kinase buffer (0.2 mM DTT, 50
mM Tris pH 7.5, 50 mM KCl) was incubated with 1 µM of recombinant HRD1 protein
containing only the RING domain (both lumenal and transmembrane domains were
excluded; Figure 4) at 37°C. Additionally, 0.3 µM of recombinant E1 protein (Boston
Biochem; Cambridge, MA), 1 µM of E2 ubiquitin-conjugating enzymes Ube2G2,
Ube2J1, UbcH5C, Ube2W (Boston Biochem; Cambridge, MA), 60 µM wild type or
lysine-specific mutant ubiquitin (Boston Biochem; Cambridge, MA), and 5 mM
MgCl2/5mM ATP were incubated with 1X kinase buffer and recombinant E3 ligase. For
reactions using the deubiquitinating enzyme ataxin-3, 1 µM was added to the reaction
mixture prior to the addition of ATP or after quenching ubiquitination reaction with
excess EDTA. At noted time points, aliquots were taken from each reaction and
supplemented with 6% boiled SDS prior to being loaded onto SDS-PAGE gels.
2.3 DNA constructs
All HRD1 DNA constructs used for mammalian cell expression (wild type, inactive
[CA], AARA, K-R) were expressed in pcDNA3.1 (Life Technologies; Carlsbad, CA). HAtagged ubiquitin for mammalian cell expression was in pRK5 and was a kind gift from
Dr. Ted Dawson (Johns Hopkins University). Other DNA constructs used have been
described before [118, 188, 196-200]. HRD1 DNA constructs were mutated (AARA, KR) using the QuikChange mutagenesis kit (Agilent; Santa Clara, CA). Small interfering
RNA (siRNA) was used to perform knockdowns in cells. Three different siRNA
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constructs for Ube2J1 (catalog numbers s28177, s28178, s28179) and Ube2G2
(catalog numbers s14583, s14584, s14585) as well as a scrambled negative control
were acquired (Life Technologies; Carlsbad, CA). Seven USP25 shRNA constructs were
purchased from Open Biosystems (Lafayette, CO) (V2LHS_63867, V2LHS_63830,
V2LHS_63903, V2LHS_63904, V2LHS_63902, V2LHS_5201, V2LHS_310311). For
bacterial expression, HRD1 and ataxin-3 were in pET21a vector.
2.4 Immunofluorescence
Immunofluorescence was performed as previously described [191]. 4%
paraformaldehyde in PBS was used to fix cells for 20 minutes before rinsing thrice with
PBT (PBS, 0.1% Triton X-100). After rinsing, cells were blocked for one hour in 5%
normal goat serum in PBT. Primary antibody (rabbit, polyclonal anti-20S (Affiniti; Exeter,
UK) and mouse, monoclonal anti-FLAG (Sigma-Aldrich; St. Louis, MO) both used at
1:500 concentration) was applied overnight. Fluorescent secondary antibodies (1:1,000;
Jackson Immunoresearch; West Grove, PA) were applied for two hours. Images were
acquired using an oil immersion lens (100X).
2.5 Immunopurifications
Immunopurifications were performed as have been previously detailed [191-193,
201]. Briefly, transfected mammalian cells were harvested and pelleted in ice-cold PBS.
Pellets were lysed with NETN lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.5%
NP-40) supplemented with complete protease inhibitor cocktail (Sigma-Aldrich; St.
Louis, MO). Following lysis, tagged protein was immunoprecipitated using agarose
beads conjugated to the epitope tag of interest (Sigma-Aldrich; St. Louis, MO) at 4°C for
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six hours. After the immunopurification, complexes were rinsed thrice with NETN plus
protease inhibitor, and subsequently eluted via 2% SDS and boiling.
For stringent immunopurifications, cells were lysed in RIPA lysis buffer (150 mM
NaCl, 50 mM Tris, 0.1% SDS, 1% NP-40, 0.5% deoxycholic acid, pH 7.4) supplemented
with protease inhibitor cocktail (Sigma-Aldrich; St. Louis, MO). Following lysis, cells
were denatured for 30 minutes at room temperature using 1% final SDS and renatured
in 4.5% final Triton X-100 for 30 minutes. Cells were then immunopurified with beadbound antibodies (Sigma-Aldrich; St. Louis, MO) and rinsed 5-8 times with RIPA lysis
buffer supplemented with protease inhibitor cocktail before elution by 2% SDS.
2.6 Mammalian cell culture
Human Embryonic Kidney (HEK)-293, HEK-293T, and HeLa (cervical epithelial
adenocarcinoma) cells used for mammalian cell transfection were purchased from
American Type Culture Collection (ATCC; Mannassas, VA). Each cell line was cultured
in Dulbecco’s modified Eagle’s medium (DMEM) (ThermoFisher Scientific; Waltham,
MA). DMEM was supplemented with 10% fetal bovine serum (HyClone Laboratories;
Logan, UT), 500 µg/ml streptomycin (Invitrogen; Carlsbad, CA) and 100 units/ml
penicillin (Invitrogen; Carlsbad, CA). Cells were grown at 37°C in 5% CO2 and were
transiently transfected with DNA plasmids after reaching ~75% confluency using
Lipofectamine LTX (Invitrogen; Carlsbad, CA) according to the manufacturer’s
suggested protocol. siRNAs, shRNAs, and additional DNA plasmids were transfected
using Lipofectamine 3000 or Lipofectamine RNAiMAX (Invitrogen; Carlsbad, CA) per
the manufacturer’s instructions. After 48 hours, transfected cells were harvested in 2%
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boiling SDS buffer (2% SDS, 10% glycerol, 100 mM DTT, 50 mM Tris pH 6.8) and
before being loaded onto SDS-PAGE gels, lysates were boiled for 10 minutes.
To mimic endoplasmic reticulum stress conditions, non-transfected HeLa cells
were grown to 80% confluency and treated with varying concentrations of DTT for 6
hours prior to harvesting. For heat shock, non-transfected HeLa cells were grown at
37°C in 5% CO2 overnight, and subsequently transferred to 42°C in 5% CO2 for 1-2
hours to induce stress [202] before harvesting. The protein concentration of each lysate
was determined prior to western blotting by the BCA Protein Assay (ThermoFisher
Scientific; Waltham, MA).
Breast cancer cell lysates were a kind gift from Dr. Julie Boerner (Karmanos
Cancer Institute) and were not cultured in the Todi laboratory. All lysates were measured
at 50 µg by the BCA Protein Assay (ThermoFisher Scientific; Waltham, MA).
2.7 Mouse tissue homogenization
The snap-frozen tissues from FVB/N male mice were generously gifted to us by
Dr. Izabela Podgorski (Wayne State University School of Medicine). The Todi laboratory
did not have any role in the initial designed use of the mice. Original experiments using
the mice and the collection of the samples gifted to us were performed by the Podgorski
laboratory and were done in accordance with their approved protocol from the Wayne
State University Animal Investigation Committee as well as in accordance with National
Institutes of Health guidelines. To analyze the expression of various ERAD components,
snap-frozen tissue samples were pulverized and homogenized with RIPA buffer
supplemented with complete protease inhibitor cocktail (Sigma-Aldrich; St. Louis, MO).
After lysis, samples were briefly sonicated and centrifugated for 15 minutes at 13,000 x
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G at 4°C. BCA Protein Assay (ThermoFisher Scientific; Waltham, MA) was used to
determine the protein concentration of each tissue sample prior to loading onto SDSPAGE gels.
2.8 PCR-based analyses
TRIzol reagent (Invitrogen; Carlsbad, CA) was used to extract total RNA from cells.
TURBO DNAse (Ambion; Carlsbad, CA) was used after RNA isolation to eliminate any
potential confounding DNA contamination. For quantitative RT-PCR, total RNA was
extracted using TRIzol and treated with TURBO DNAse (Ambion; Carlsbad, CA) to
eliminate trace DNA. The High Capacity Kit (Applied Biosciences; Carlsbad, CA) was
used to perform reverse transcription and samples were quantified using fast SYBR
Green (Applied Biosciences; Carlsbad, CA) with the PlusOne real-time quantitative
system (Applied Biosciences; Carlsbad, CA). Primer sequences are as follows and are
human (h) constructs:
Table 1: PCR primer sequences
Primer Name

Sequence (5’ - 3’)

h-HRD1-Forward

CGCATTGTCTCTCTTATGTTCCTC

h-HRD1-Reverse

GTAGAGCATGTACACAGCCTTGTT

h-Ube2G2-Forward

CCACTTGATTACCCGTTAAGTCC

h-Ube2G2-Reverse

ACAGCAGGATCTTCTCCACACT

h-Ube2J1-Forward

GAATGGCACTTCACGGTTAGAG

h-Ube2J1-Reverse

GCCTGAGATGCTCAAACAGATT

h-Ube2W-Forward

GTGGATTGTAGACATGGAAGGTG

h-Ube2W-Reverse

GGACCAGTCTTCTGTTAGAATGGA

h-IRE1-Forward

GGATTTTTGGAAGTACCAGCAC
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Table 1: PCR primer sequences
Primer Name

Sequence (5’ - 3’)

h-IRE1-Reverse

GTATACAGGCTGCCATCATTAGC

h-PERK-Forward

GAACCAGACGATGAGACAGAGTT

h-PERK-Reverse

CCCAAATACCTCTGGTTTGCTA

h-GAPDH-Forward

GCTCAGACACCATGGGGAAGGT

h-GAPDH-Reverse

GTGGTGCAGGAGGCATTGCTGA

2.9 Proteasomal inhibition
Cells used for mammalian cell culture were grown to transfection confluency per
the manufacturer’s suggested protocol. Forty-eight hours post-transfection, cells were
treated with 15 µM MG132 (AG Scientific; San Diego, CA) for 0-6 hours prior to
harvesting cells by boiling SDS/DTT lysis buffer. Cell lysates were electrophoresed for
western blotting analysis.
2.10 Pulse-chase analyses
Cells were grown to 70-75% confluency and transiently transfected with prepared
DNA constructs. After 48 hours, cells were treated with 75 µg/ml cycloheximide (AG
Scientific; San Diego, CA) dissolved in pure water, or with vehicle control for up to 6
hours. After treatment, cells were harvested using boiling SDS lysis buffer and loaded
onto SDS-PAGE for western blotting.
2.11 Western blot analyses, quantification, and statistical analyses
For all SDS-PAGE, 10%, 15% or 4-20% gradient gels were used, and transferred
on PVDF membranes (Bio-Rad; Hercules, CA). Western blots were imaged using the
VersaDoc 5000MP (Bio-Rad; Hercules, CA) and quantified using Quantity One software
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(Bio-Rad; Hercules, CA) as previously described [203]. Student T-tests were used for
statistical analyses.
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CHAPTER 3 - HRD1 AND ASSOCIATED UBIQUITIN-CONJUGASES IN ERAD
3.1 General introduction and hypothesis
ERAD is a critical component of protein quality control in the ER responsible for
maintaining homeostasis of the cellular machinery [107, 204]. Central to ERAD’s ability
to recognize and remove aberrant polypeptides from the ER lumen is the function of E3
ubiquitin ligases. HRD1 is a resident E3 ubiquitin ligase on the ER membrane and is
primarily responsible for the recognition of misfolded or toxic proteins inside the ER.
HRD1 in mammals has been reported to interact with at least two different E2 ubiquitinconjugases: Ube2G2 and Ube2J1 [96, 118]. Because ERAD is found in a wide range of
tissues and systems, and aberrant ERAD, is implicated in a number of physiologicallydistinct diseases, we hypothesized that different types of ERAD operate in different
tissue and in normal and disease states. Longer term, we wanted to understand how
ERAD components interact to yield different outcomes (i.e. normal versus disease
states). We examined the expression of HRD1 and the ubiquitin-conjugases Ube2G2
and Ube2J1 in mouse tissue.
3.2 HRD1 is expressed with ubiquitin-conjugases in mouse tissue
We used six different tissue types, each with varying physiological function in vivo,
to examine the expression of HRD1 and other ERAD proteins with which it is known to
interact. HRD1 is expressed abundantly both in the kidney and spleen, and HRD1
expression is clear in the brain, albeit not as robustly as in the kidney or spleen (Figure
6). Additionally, endogenous HRD1 cannot be detected in the skeletal muscle tissue or
the heart, but is slightly visible in the lung (Figure 6). In mouse tissues, the anti-HRD1
antibody in the laboratory
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FIGURE 6: HRD1 IS EXPRESSED WITH DIFFERENT UBIQUITIN-CONJUGASES IN
MOUSE TISSUE
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FIGURE 6: HRD1, Ube2G2 and Ube2J1 expression in different mouse organs. Male,
FVB/N mouse tissue was homogenized in RIPA lysis buffer in the presence of a
protease inhibitor cocktail (Materials and Methods). 100 µg of total protein was loaded
in each lane as determined by BCA protein assay. Two different loading controls (antiGAPDH, anti-Tubulin) are shown to demonstrate variability among the different
samples in proteins used for loading.
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FIGURE 7: PROTEIN CODING ISOFORMS OF MOUSE HRD1 (PREDICTED)
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FIGURE 7: Hrd1 genomic sequences were aligned using the ClustalW2 multiple
sequence alignment tool. The VCP/p97 binding domain of HRD1 is highlighted in red
font. The predicted molecular weights of each protein coding isoform are shown in
blue as determined by ProtParam.
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detects two distinct bands. Because there are at least five protein coding isoforms of
hrd1 in mice [205], the endogenous bands detected by the antibody may represent
different isoforms of HRD1. Using ProtParam, an online tool which computes physical
and chemical components of a protein, the two bands we observe in these tissues could
be isoforms 1 and 5 (Figure 7). Both isoforms 1 and 5 contain the arginine-rich VCP/p97
binding domain.
We know that Ube2G2 and Ube2J1 functionally interact with HRD1 [96, 118], so
we examined the expression of these two ubiquitin-conjugases in the same mouse
tissue that we found HRD1 to be expressed (Figure 6). Interestingly we found that
HRD1 and Ube2G2 are expressed in different tissue samples than HRD1 and Ube2J1.
For example, HRD1 and Ube2G2 are expressed together in the kidney, but not as much
in the brain (Figure 6). Conversely, HRD1 and Ube2J1 are both expressed in the brain,
but not in the kidney (Figure 6).
3.3 HRD1 is expressed with ubiquitin-conjugases in breast cancer cell lines
Examining the expression of ERAD components in mouse tissue led us to
consider that indeed HRD1 may collaborate with different ubiquitin-conjugases
depending on the tissue in which the ER stress is occurring. We wondered whether
HRD1 and the ubiquitin-conjugases Ube2G2 and Ube2J1 demonstrate variable
expression patterns in different cancer cell lines, which would suggest the collaboration
of ERAD components depends on the tissue and disease type.
3.3.1 Invasive ductal carcinoma
The breast cancer cell lysates that were used in this study are all subtypes of a
breast cancer diagnosis of invasive ductal carcinoma (IDC) which, according to the
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National Cancer Institute, is characterized by cancer cells breaking through the basal
membrane of the ductal epithelium and invading the surrounding lymphatic and tissue
systems. IDC is further characterized by specific properties of the tumor itself in order to
gauge prognosis and determine an appropriate treatment plan. Most notably, the
hormone status of the tumor is an important prognostic indicator for the patient because
the molecular profile of the tumor sometimes determines the treatment plan (other than
tumor morphology). The presence of two different hormone receptors - estrogen
receptor and progesterone receptor - are commonly screened for variations in their
molecular profile [206]. In addition to these hormone receptors, a growth factor receptor
known as human epidermal growth factor receptor 2 (HER2) is commonly amplified and
included in the molecular screen [206]. However, the most aggressive subtype is the
triple-negative, basal-like breast cancer where aberrant tumor cells are estrogen
receptor and progesterone receptor negative, and are lacking enrichment by HER2
[206]. These patients suffer from a poor prognosis and their cancer is extremely
invasive and aggressive.
3.3.2 ERAD protein expression in breast cancer cell lines
We acquired cell lysates from three different molecular subtypes of human breast
cancer (estrogen receptor positive, HER2 positive, and the basal-like triple-negative)
and we examined this panel of cell lines for the expression of HRD1 and the ubiquitin
conjugases Ube2G2 and Ube2J1 (Figure 8). Tumor cell lines positive for estrogen
receptor each express HRD1 abundantly, although the ubiquitin-conjugase Ube2G2
was expressed at near equal level in each sample. Conversely, Ube2J1 is highly
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FIGURE 8: PROTEIN EXPRESSION OF HRD1 AND OTHER ERAD COMPONENTS
IN BREAST CANCER CELL LYSATES
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FIGURE 8: HRD1, Ube2G2, and Ube2J1 expression in three different subtypes of
breast cancer: estrogen receptor positive (red), HER2 positive (blue), and triple
negative (purple). Lysates were loaded at 50 µg/lane concentrations as determined by
BCA protein assay.
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expressed in the SUM44 cell line, but not as readily expressed in the MCF7 cell line
which may reflect more specific differences in the characterization of these cell lines.
In the HER2 positive cell lines, HRD1 protein is expressed across the board at
near equal levels with the exception of two cell lines; SUM52 and SUM225 have
diametrically opposite protein expression levels of HRD1. The SUM225 line abundantly
expresses HRD1 protein whereas the SUM52 cell line does not contain endogenous
HRD1. This suggests that perhaps an ubiquitin ligase other than HRD1 is responsible
for E3 activity in this type of breast cancer (e.g. GP78, perhaps), or perhaps the
attempts at homeostasis in this disease model uses a different mechanism of
degradation that bypasses HRD1. All HER2 positive cell lines tested expressed both
Ube2G2 and Ube2J1 protein, suggesting that these ubiquitin-conjugases are involved in
maintaining proper protein folding to degradation rates.
The most aggressive disease in vivo, triple-negative cell lines, mostly all express
HRD1, Ube2G2 and Ube2J1 protein at very similar levels, although a few cell lines have
interesting characteristics. The BT549 cell line abundantly expresses HRD1 protein,
although the endogenous levels of Ube2G2 and Ube2J1 are low suggesting that HRD1
may cooperate with unidentified ubiquitin-conjugases in breast cancer with this specific
molecular profile. SUM159 breast cancer cells do not express HRD1 protein at the
endogenous level, but highly express Ube2J1 indicating that this ubiquitin-conjugase
perhaps functions with a different ubiquitin ligase in quality control. Lastly, in MDAMB-468 cells, HRD1 and both Ube2G2 and Ube2J1 are all expressed at high
endogenous protein levels suggesting that these proteins work together in this tumor
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cell line in ERAD, but does not rule out the possibility that other ligases and conjugases
could be working together with HRD1, Ube2G2 and Ube2J1.
3.4 Dynamic regulation of ERAD components during stress in cultured cells
HRD1 is divergently expressed along with ubiquitin-conjugases Ube2G2 and
Ube2J1 in different tissues and this co-presence also varies based on the molecular
profile of disease in breast cancer (Figures 6, 8). We wondered if different inducers of
cellular stress cause dynamic expression of ERAD components in cells. Here, we
examined HRD1 and the ubiquitin-conjugases Ube2G2, Ube2J1, and Ube2W under
cultured cell stress conditions. Ube2W is an E2 ubiquitin-conjugase that interacts with
the E3 HECT family ligase CHIP, and ubiquitinates substrates at the N-terminus [195,
207]. Because CHIP is implicated in protein quality control by targeting substrates for
proteasomal degradation, we wondered whether Ube2W collaborates with HRD1 in
ERAD as well. Unfortunately, due to the lack of a reliable antibody available for Ube2W,
we were unable to examine the endogenous levels of this particular ubiquitin-conjugase
in tissue and breast cancer cell lines.
Cellular stress in non-transfected HeLa cells was induced using a pharmacological
ER stress inducer (DTT) as well as a physiological ER stress inducer (heat shock). The
reducing agent DTT prevents disulfide-bond formation and therefore is a pan-inducer of
cellular stress by causing the accumulation of proteins in both the ER lumen and in the
cytoplasm. Physiologically, the increased synthesis of the heat shock protein family of
chaperones is a generic indicator of induced cellular stress.
We examined the mRNA and protein levels of HRD1, and the ubiquitin-conjugases
Ube2G2, Ube2J1, and Ube2W after the induction of ER stress by DTT and heat shock
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using non-transfected HeLa cells in order to determine if certain collaborations between
HRD1 and the ubiquitin-conjugases with which it interacts take place under different
stress conditions (Figure 9). The transcript levels of all four ERAD components varied
under pharmacological (Figure 9A) and physiological (Figure 9B) stress. Despite the
absence of a clear dose-dependent increase at the mRNA level for either stressor,
HRD1 and its collaborating ubiquitin-conjugases are dynamically regulated at the
expression level in response to ER stress.
Next, we examined the mRNA level of ER stress sensors IRE1 and PERK and
noticed a clear induction of the PERK stress signal with both the DTT treatment and
heat shock, as well as an increase at the protein level for Hsp70, a heat shock protein
chaperone that is induced under environmental stress conditions (Figure 9B).
The expression of Ube2G2 and Ube2J1 at the protein level does not match what is
demonstrated at the mRNA level, and although somewhat discouraging, perhaps
indicates that the turnover of each protein is different in a stressor-specific basis.
Together, these data (Figures 6, 8 and 9) suggest that HRD1 collaborates with different
ubiquitin-conjugases in ERAD depending on the tissue where the injury is located, the
type of disease caused by the overwhelming stress, and what kind of stress is causing
the accumulation of proteins.
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FIGURE 9: COLLABORATION OF ERAD COMPONENTS UNDER
PHARMACOLOGICAL AND PHYSIOLOGICAL ER STRESS
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FIGURE 9: HRD1 and the ubiquitin-conjugases Ube2G2, Ube2J1, and Ube2W
mRNA and protein expression under induced ER stress conditions. Cell stress was
induced in HeLa cells using varying concentrations of DTT or placed under heat shock
for 1-2 hours. DTT treatment lasted for 6 hours before cells were harvested. Heat
shock conditions were mimicked by placing cells in 42°C incubator with 5% CO2. IRE1
and PERK are ER stress reporters.
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CHAPTER 4 - HRD1 FORMS DIFFERENT POLYUBIQUITIN CHAINS IN VITRO
4.1 General introduction and hypothesis
Over the years, significant work has been done examining the ERAD pathway and
the role(s) of HRD1 in it. Besides being a major player in the ERAD pathway due to its
innate ligase function, HRD1 is one of the better characterized mammalian ubiquitin
ligases. Additionally, as previously discussed, HRD1 is an essential gene in mammals
as it has been demonstrated that HRD1 null mice are embryonic lethal [120]. Despite
being known to interact with Ube2G2 and Ube2J1, the role(s) of HRD1 in ERAD are still
largely unclear. In order to better understand how ERAD works in normal and disease
states, it is essential to understand how the proteins implicated in this pathway function
together. Several unresolved questions remain regarding HRD1’s role in the ERAD
pathway. We hypothesized that HRD1 forms different ubiquitin-ubiquitin linkages in
vitro with different ubiquitin-conjugases. This is important because the type of ubiquitin
linkage determines the fate of each substrate protein and dysregulation in this system
could be a potential factor in disease.
4.2

Recombinant HRD1 forms polyubiquitin chains in vitro with Ube2G2 and

Ube2J1
In order to examine the type(s) of ubiquitin chains HRD1 forms with the ubiquitinconjugases it is known to interact, we used an in vitro biochemical system using purified
proteins. This allowed us to precisely understand the potential HRD1/ubiquitinconjugase functional interaction. In order to asses ubiquitin linkages made by HRD1, we
used a recombinant HRD1 construct that contained the catalytic RING domain and the
remainder of the cytoplasmic domain of the protein (Figure 4A; red arrow to amino acid
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617). This recombinant HRD1 excludes the ER luminal portion and transmembrane
domains of the ligase listed in black font in the HRD1 amino acid sequence (Figure 4B).
The cytoplasmic amino acid residues of HRD1 are listed in red, and highlights
individually the catalytic cysteine in the RING domain (green; Figure 4B), lysine
residues mutated in future experiments (blue; Figure 4B), and the arginine motif of
HRD1 that binds VCP/p97 (purple; Figure 4B).
We first wanted to test the activity of the recombinant HRD1 in vitro so we
examined its ability to form ubiquitin chains with four different E2 ubiquitin-conjugases:
UbcH5C (which has been reported to function in vitro with HRD1 [118]), Ube2G2,
Ube2J1, and Ube2W (a novel E2 ubiquitin-conjugating enzyme that enhances the
activity of certain ubiquitin ligases, such as CHIP [195]). HRD1 made in bacteria
generates polyubiquitin species with UbcH5C rapidly (Figure 10A). Without an E2
ubiquitin-conjugase present in the reaction, our recombinant HRD1 protein does not
produce any ubiquitin conjugates (Figure 10A). The arrow in the anti-ubiquitin blot for
the reaction containing UbcH5C identifies where the unmodified version of HRD1 would
migrate. The anti-HIS blot shows the progressive ubiquitination of HRD1 (Figure 10A).
Examining the interaction between HRD1 and the ubiquitin-conjugase Ube2W shows
something slightly different. Unlike with UbcH5C, HRD1 in the presence of Ube2W
forms only mono-ubiquitin species (Figure 10B).
Next, we wanted to examine the activity of recombinant HRD1 with the ubiquitinconjugases Ube2G2 and Ube2J1 (Figure 11). Indeed, HRD1 forms polyubiquitin
linkages in the presence of both Ube2G2 (Figure 11A) and Ube2J1 (Figure 11B).
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FIGURE 10: HRD1 FORMS DIFFERENT UBIQUITIN CHAINS WITH
UBCH5C AND UBE2W
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FIGURE 10: In vitro ubiquitination assays demonstrating the activity of recombinant
HRD1 to form ubiquitin conjugates in the presence of UbcH5C (A) and Ube2W (B).
Reactions were set up as described in Materials and Methods. Aliquots were taken at
specific time points listed above and loaded onto SDS-PAGE gels for western blotting.
Arrow in (A) identifies where the unmodified version of HRD1 would migrate. Western
blots are representative of at least three independent experiments, with similar results.
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FIGURE 11: HRD1 FORMS POLYUBIQUITIN CHAINS WITH UBE2G2 AND UBE2J1
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FIGURE 11: In vitro ubiquitination assays demonstrating the activity of recombinant
HRD1 to form ubiquitin conjugates in the presence of Ube2G2 (A) and Ube2J1 (B).
Reactions were set up as described in Materials and Methods. Aliquots were taken at
the specific time points and loaded onto SDS-PAGE gels for western blotting. Long
exposure for anti-His blot in (B) is to demonstrate ubiquitinated HRD1 bands. Blots
are representative of at least three independent experiments, with similar results.
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FIGURE 12: UBE2W ENHANCES POLYUBIQUITIN CHAIN FORMATION

FIGURE 12: In vitro ubiquitination assays demonstrating the activity of recombinant
HRD1 to form ubiquitin conjugates in the presence of Ube2G2 (A) and the equimolar
concentration of both Ube2G2 and Ube2W (B). Reactions were performed as
described in Materials and Methods. Aliquots were taken at the specific time points
and loaded onto SDS-PAGE gels for western blotting. Blots are representative of at
least three independent experiments, with similar results.
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Based on the anti-ubiquitin and anti-HIS western blots, the chains formed by HRD1 in
vitro in the presence of Ube2G2 are composed of unanchored chains, as well as
unmodified and auto-ubiquitinated Ube2G2 and HRD1 (Figure 11A; modified species
denoted by arrows). Conversely, recombinant HRD1 in the presence of Ube2J1 forms
predominantly unmodified and ubiquitinated Ube2J1 and little ubiquitinated HRD1
(Figure 11B; little ubiquitin signal in upper portion of ubiquitin blot - long exposure to
emphasize ubiquitinated HRD1). This is additional evidence that perhaps HRD1 and
Ube2J1 require collaborations with other protein partners to form ubiquitin conjugates,
as compared to the readily formed ubiquitin chains by HRD1 with Ube2G2.
Interestingly, Ube2W dramatically enhances polyubiquitin chain formation by
HRD1 and Ube2G2 (Figure 12). Because Ube2W itself cannot directly lead to ubiquitin
chain formation (Figure 10B) with HRD1 or with another ligase tested [195], these data
indicate that Ube2W controls the ubiquitin chain forming activity of HRD1, and suggests
that it might regulate HRD1 in cells.
4.3 Recombinant HRD1 forms specific ubiquitin linkages in vitro
Knowing that HRD1 forms polyubiquitin chains with at least Ube2G2 and Ube2J1
in vitro (Figure 11), we wondered if HRD1 displays any type of ubiquitin linkage
specificity (Figure 13) with these ubiquitin conjugases. To do this, we utilized
recombinant ubiquitin mutants that contain only a single lysine residue on ubiquitin, with
the other six lysine residues mutated to non-ubiquitinatable arginine. In the presence of
UbcH5C, recombinant HRD1 does not display much ubiquitin chain specificity, forming
various types of linkages (Figure 13A). On the other hand, HRD1 and Ube2G2 form
specifically K48-linked ubiquitin chains
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FIGURE 13: HRD1 DISPLAYS UBIQUITIN CHAIN PREFERENCE IN VITRO
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FIGURE 13: In vitro ubiquitination assays where recombinant UbcH5C (A), Ube2G2
(B), and Ube2J1 (C) was combined with HRD1 in the presence of single ubiquitin
mutants, where the ubiquitin construct contains only one ubiquitin residue, or none at
all (KØ). Each reaction was timed for one hour and the product was loaded for
western blotting. The Ube2J1 arrow in (C) identifies ubiquitinated Ube2J1 protein.
Each panel is a representative western blot from at least three separate experiments,
with similar results.
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(Figure 13B). This is important and physiologically significant because K48-linked
chains predominantly target substrate proteins to the proteasome for degradation [69].
Interestingly, HRD1 in the presence of Ube2J1 mostly forms unconventional K11-, K29-,
and K33-linked ubiquitin species. K29-linked polyubiquitin chains have recently been
proposed to be present within branched and/or mixed ubiquitin chains that are
composed of other polyubiquitin linkages [208]. Additionally, these non-canonical chains
have historically been linked to proteasome-independent substrate degradation via
lysosomes and have diverse roles in cellular regulation [209-212]. Although the function
of these alternative ubiquitin chains in ERAD is not well known, our data suggest that
the type of polyubiquitin chain HRD1 forms in vitro depends on the ubiquitin-conjugase
present.
These results regarding HRD1 displaying ubiquitin chain preference depending on
the ubiquitin-conjugase with which it interacts are interesting because literature
research has not shed light on HRD1 chain specificity with varying conjugases in ERAD.
Other data in the field have demonstrated that the type of ubiquitin linkage formed by
ubiquitin ligases in the RING family is determined by the E2 conjugase that it interacts
with [213, 214]. Examples of this include the ligases CHIP and BARD1-BRCA1, which
form K48- or K63-linkages depending on the ubiquitin-conjugase the ligases interact
with [215-217]. Together, our results (Figure 11, 13) indicate this is the case for HRD1
as well.
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CHAPTER 5 - HRD1 REQUIRES UBIQUITIN-CONJUGASES UBE2G2 AND UBE2J1
IN CELLS TO FORM UBIQUITIN LINKAGES
5.1 General introduction and hypothesis
Using in vitro protein biochemistry is an efficient way to determine the functional
relationships between proteins. The in vitro experiments (Figures 10-13) suggest that
the type of polyubiquitin generated by HRD1 depends on the ubiquitin-conjugase
present in the complex. Consequently, we sought to identify how HRD1 forms specific
ubiquitin linkages in cells, and hypothesized that HRD1 requires either Ube2G2 or
Ube2J1 to form polyubiquitin chains on protein substrates in cells. To do this, we used
transient transfections and co-immunoprecipitations to identify specific ubiquitin chains
formed by HRD1. Additionally, we used ubiquitin antibodies that specifically detect K48linked or K63-linked polyubiquitin. We did not have access to ubiquitin antibodies
specific to other lysine residues. The results from these experiments will help identify
the collaborations HRD1 forms in cells, which may be useful for delineating the
regulation of ubiquitination in ERAD.
5.2 HRD1 does not exclusively auto-ubiquitinate in cells
In order to identify the ubiquitin chains formed by HRD1 in cells, we examined the
polyubiquitin species co-immunoprecipitated by HRD1. Due to its innate role as an E3
ubiquitin ligase, HRD1 can self-ubiquitinate (e.g. Figure 11). Because we wanted to
ensure the polyubiquitin species co-immunoprecipitated by HRD1 are not anchored
onto HRD1 itself, we created a lysine-deficient HRD1 construct where the lysine
residues in the cytoplasmic portion of the protein after the transmembrane domain are
mutated into the similar, but non-ubiquitinatable amino acid arginine (Figure 4). As
demonstrated in Figure 14, the wild type version of HRD1 and its lysine-deficient
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counterpart each co-immunoprecipitate similar amounts of polyubiquitin, providing
support that the polyubiquitin species immunoprecipitated by HRD1 are not autoubiquitinated HRD1 species (Figure 14). Additionally, the catalytic RING activity of
HRD1 is essential for it to co-immunoprecipitate ubiquitin conjugates. Using a
catalytically inactive version of HRD1 (cysteine 291 mutated to alanine [118]), the
mutant HRD1 co-precipitates very little ubiquitin species compared to the wild type
version (Figure 15A). The small amount of polyubiquitin species we do see coprecipitate with the inactive version of HRD1 is likely due to endogenous HRD1
because HRD1 proteins are able to interact with each other in cells (Figure 15B).
5.3 HRD1 forms K48- and K63-linked ubiquitin species in cells with the ubiquitinconjugases Ube2G2 and Ube2J1
For us to identify the importance of the ubiquitin-conjugases Ube2G2 and Ube2J1
with HRD1 in the formation of polyubiquitin chains, we co-transfected small interfering
RNA (siRNA) targeting the endogenous conjugases alongside wild type HRD1 (Figure
16). In the presence of endogenous Ube2J1 (Figure 16A) and Ube2G2 (Figure 16B),
wild type HRD1 co-precipitates K48- and K63-linked polyubiquitin conjugates.
Conversely, RNAi-dependent knockdown of Ube2J1 (Figure 16A) and Ube2G2 (Figure
16B) leads to a significant decrease in the amount of co-precipitated polyubiquitin
species by HRD1 in cells. Because the knockdown of each ubiquitin-conjugase in cells
leads to a decrease in K48-linked and K63-linked polyubiquitin, this indicates that HRD1
does indeed make at least both K48 and K63 polyubiquitin chains in cultured
mammalian cells with Ube2G2 and Ube2J1.
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FIGURE 14: CO-IMMUNOPRECIPITATED POLYUBIQUITIN SPECIES BY HRD1 ARE
NOT AUTO-UBIQUITINATED HRD1
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FIGURE 14: HEK-293T cells were transfected with the indicated constructs and
harvested 48 hours post-transfection. Harvested cells were lysed and incubated with
bead-bound antibody against the V5-tag on HRD1. Immunoprecipitated protein was
loaded onto SDS-PAGE gels for western blotting. The anti-K63- and anti-K48-linked
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domain of HRD1 for all four lysine residues. The panel represents at least three
separate independent experimental repeats with similar outcomes.
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FIGURE 15: THE CATALYTIC RING DOMAIN IS IMPORTANT FOR HRD1’S
LIGASE FUNCTION
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FIGURE 16: KNOCKDOWN OF ENDOGENOUS UBIQUITIN-CONJUGASES IN
CELLS IMPACTS THE ABILITY OF HRD1 TO MAKE POLYUBIQUITIN CHAINS
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FIGURE 16: (A, B) HEK-293T cells were transfected with the indicated constructs and
harvested 48 hours post-transfection, lysed and incubated with bead-bound antibody
against the V5-tag on HRD1 for 6 hours. Immunoprecipitated protein was loaded onto
SDS-PAGE gels for western blotting after washing and elution through a combination
of SDS and heat. The histograms for each western blot represent the quantification of
the ubiquitin signal in each IP lane, normalized to the HRD1 signal in the IP lanes +/standard deviations (SD), then normalized to the polyubiquitin co-immunoprecipitated
by wild type HRD1. Error bars represent SD. P values are calculated from two-tailed
Student T-tests. For each panel, western blots are representative of at least three
separate independent trials with similar outcomes.
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However exciting, these results (Figure 16) do not coincide with the role of
polyubiquitin chain formation by HRD1 demonstrated using in vitro biochemistry (Figure
13) where we observe the generation of K48-linked ubiquitin chains by the partnership
of HRD1 and Ube2G2, and the formation of non-canonical (K11-, K29-, K33-linked
ubiquitin) chains by HRD1 with Ube2J1. In cells, HRD1 generates at least K48- and
K63-linked polyubiquitin with either conjugase (Ube2G2 or Ube2J1) present (Figure 16).
Together, these data indicate the need for the use of the HRD1 holo-enzyme in
polyubiquitin chain formation made with either ubiquitin-conjugase. This is likely the
case especially for Ube2J1, because in vitro we do not observe K48-linked ubiquitin
chains being formed by the HRD1/Ube2J1 partnership. Alternatively, as previously
discussed, HRD1 and the ubiquitin-conjugases Ube2G2 and Ube2J1 may interact with
other proteins that assist in this collaboration to make specific types of chains in
different model systems (in vitro versus in cells).
Interestingly, HRD1 seemingly demonstrates the ability to form K63-linked ubiquitin
chains in cells (Figure 16). K63-linked ubiquitin species are generally believed to
function in non-proteasomal roles, such as autophagy [218]. This suggests that HRD1
may have additional roles outside the realm of ERAD that depend on its ability to form
K63-linked ubiquitin chains, or perhaps some ERAD protein substrates are degraded by
K63-linked ubiquitin signaling.
5.4 The VCP/p97 binding domain on HRD1 is important for polyubiquitin chain
formation
As previously detailed, VCP/p97 is a AAA ATPase that monitors critical steps in
several protein quality control processes, including ERAD [123, 219]. The dogma
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surrounding VCP/p97 is that it functions post-ubiquitination of protein substrates, aiding
in their extraction into the cytosol and guiding them to the proteasome for degradation
[130, 131]. Unlike in yeast, HRD1 directly interacts with VCP/p97 in mammalian cells
through an arginine rich, four amino acid long motif near its C-terminal end [110, 111]. In
order to investigate the importance of this VCP/p97 binding domain on HRD1 in the
generation of polyubiquitin chains, we used site-directed mutagenesis to change the
RRRR VCP/p97 binding sequence on HRD1 into AARA, which prevents HRD1 from
binding endogenous VCP/p97 protein (Figure 17).
By expressing HRD1 that does not bind VCP/p97 (referred to as HRD1-AARA) in
mammalian cells, we found that HRD1-AARA co-immunoprecipitates less polyubiquitin
than the wild type version of HRD1 with its VCP/p97 binding domain intact (Figure 18).
This suggests that while the interaction between VCP/p97 and HRD1 is not absolutely
necessary for the generation of polyubiquitin by HRD1, it is important for the formation
of some species.
The findings from figures 14-18 lead us to surmise that the HRD1-associated
ubiquitin species are ones formed by this E3 ligase, potentially on its substrates: the
abundance of the ubiquitin species co-immunoprecipitated by HRD1 depends on its
activity, is not reduced by lysine-to-arginine mutations in the cytoplasmic region of
HRD1 thus addressing the concern that they are self-ubiquitinated HRD1 species, and
is not fully eliminated by preventing catalytically inactive HRD1 (HRD1-CA) from binding
to VCP/p97. The identity of the ubiquitinated proteins remains to be determined and
would benefit from mass-spectrometry analyses of HRD1-associated complexes from
cells.
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Our data hint that VCP/p97 may play multiple regulatory roles during ERAD: not only
during substrate extraction and degradation, but possibly also during ubiquitination.
VCP/p97 is a critical component of cellular processes; mutations in it lead to disease
and it is encoded by an essential gene [220, 221]. Historically, this AAA ATPase is
thought to unwind proteins out of the ER toward proteasomal “delivery”, or to function as
a segregase by removing from the ER proteins prone to proteolytic degradation [124,
125, 130, 222]. The HRD1 interaction with VCP/p97 is perhaps a regulatory feature for
this ligase in vivo. Figure 7 demonstrates that some of the predicted protein coding
isoforms of the hrd1 gene in mice do not contain the VCP/p97 binding domain. It is
possible that the expression of these particular HRD1 isoforms that do not directly
interact with VCP/p97 controls the polyubiquitin linkages generated by the ligase and
therefore impacts the types of substrates targeted by ERAD for degradation. The role of
VCP/p97 in the regulation of polyubiquitin chain formation by HRD1 could be an
evolutionary development in vertebrates (Figure 19), and perhaps indicates an
enhancement in the tuning of the ERAD pathway in higher organisms. Precisely how
VCP/p97 might regulate HRD1 activity is not clear, but could involve the AAA ATPase
functioning as a scaffold for various HRD1 partners during the ubiquitination of some
ERAD substrates.
There is another potential explanation that may account for the reduction in ubiquitin
species co-immunoprecipitated by HRD1 that does not bind VCP/p97. VCP/p97 binds
ubiquitin species through various interactors. Therefore, precluding HRD1 from
interacting with VCP/p97 could lead to a reduction in ubiquitin species
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FIGURE 17: MUTATION IN THE VCP/p97 BINDING SITE ON HRD1 PRECLUDES
BINDING TO ENDOGENOUS VCP/p97 PROTEIN
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FIGURE 17: HEK-293T cells were transfected with the indicated constructs and
harvested 48 hours post-transfection, lysed and incubated with bead-bound antibody
against the Myc-tag on HRD1 for 6 hours. Immunoprecipitated protein was loaded
onto SDS-PAGE gels for western blotting after washing and elution. Transfected
conditions were done in duplicate for each experimental repeat and were loaded with
equal volumes of lysate. Western blots are representative of at least three separate
independent trials with similar outcomes.
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FIGURE 18: VCP/p97-BINDING DOMAIN OF HRD1 IS IMPORTANT TO MAKE
POLYUBIQUITIN CHAINS IN CELLS
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FIGURE 18: HEK-293T cells were transfected with the indicated constructs. Cells
were harvested 48 hours post-transfection, lysed and incubated with bead-bound
antibody for 6 hours. Immunoprecipitated protein was loaded onto SDS-PAGE gels for
western blotting. Histograms represent the quantification of K48 and K63 ubiquitin
signal in the IP lanes, normalized to the HRD1 signal in IP +/- standard deviations
(SD). Error bars represent SD and P values were calculated using two-tailed Student
T-tests. Western blots are representative of at least nine separate independent trials
with similar outcomes.
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co-immunoprecipitated by HRD1 simply as a result of removing a contribution by
ubiquitin species bound to the AAA ATPase. This explanation, however, is not likely
since catalytically inactive HRD1 does not co-immunoprecipitate appreciable levels of
ubiquitin species (Figure 15A and other data not shown), even though this form of the
ligase does bind VCP/p97 (Figure 15A). We conclude that the reduction in ubiquitin
species as a result of the inability of HRD1 to interact with VCP/p97 is due to diminished
polyubiquitin chain formation by the ligase when it does not bind VCP/p97.
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FIGURE 19: PREDICTED HRD1 GENES IN DIFFERENT MODEL ORGANISMS
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FIGURE 19: The predicted protein coding isoforms of HRD1 obtained by the Ensembl
Genome Browser [205] were aligned using ClustalW2. The VCP/p97 binding motif on
each isoform is highlighted in red font and is noticeably conserved throughout
vertebrate species selected.
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CHAPTER 6 - THE COLLABORATION BETWEEN HRD1 AND DEUBIQUITINATING
ENZYMES IN ERAD
6.1 General introduction
As has been reiterated several times, ubiquitination of misfolded, toxic, or shortlived proteins is central to ERAD and, more generally, to protein quality control. This
ubiquitination is important for maintaining cellular homeostasis by helping prevent the
accumulation of proteins in the lumen or cytoplasm that could potentially lead to severe
human diseases including malignancy and neurodegeneration. Ubiquitination is
reversible and deubiquitination, accomplished by proteases called deubiquitinating
enzymes (DUBs), is critical for cell function [139, 223]. The roles of DUBs in ERAD have
been summarized in Section 1.3; however some further detail will be supplied here
regarding the role(s) of two different DUBs and their collaboration with HRD1: ataxin-3
and USP25.
A major question in ERAD is unresolved: How is the balance between protein
degradation and protein rescue achieved? Functional interactions between E3 ubiquitin
ligases (which can target proteins for proteasomal degradation), DUBs (which can
reverse protein ubiquitination and rescue degradation), and proteasome shuttle proteins
(like VCP/p97) are at the crux of optimal protein quality control. Therefore, we
hypothesized that functional interactions between HRD1 and ataxin-3 or USP25, and
VCP/p97 and ataxin-3 or USP25 dictate the turnover of ERAD substrates.
6.2 Ataxin-3 and ERAD
Ataxin-3 has been implicated in ERAD [146, 196], although its exact roles are
uncertain. Two groups have reported divergent roles for ataxin-3 function in protein
quality control. One group reported that ataxin-3 competes with ubiquitinated ERAD
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substrates for binding to VCP/p97, essentially reducing the degradation of misfolded ER
proteins [196]. Conversely, another report proposed that ataxin-3 deubiquitinates
substrates bound by VCP/p97 at the proteasome, enhancing their delivery to be
enzymatically degraded [146]. It is possible that ataxin-3 can both inhibit and facilitate
degradation of ERAD substrates, depending on the ERAD components with which it
interacts. VCP/p97 is not the only ERAD component with which ataxin-3 interacts; the
other as mentioned in detail in Chapters 3-5, is HRD1 [146], the ER-resident ubiquitin
ligase that is upstream of VCP/p97 in ERAD [107]. To understand the role(s) ataxin-3
plays in ERAD, and whether its functions are impacted by pathogenic expansion in its
polyglutamine region, we conducted work in vitro and in mammalian cells.
6.2.1 Ataxin-3 interacts with HRD1 in cells
To begin to understand the collaboration between ataxin-3 and HRD1 in cells, coimmunoprecipitation experiments between this DUB and E3 ubiquitin ligase were
performed and it was determined that these two proteins do indeed interact in cells
(Figure 20A). In contrast to wild type ataxin-3, a pathogenic version of ataxin-3 with an
extended polyglutamine region interacts less readily with HRD1 (Figure 20A). Neither
wild type nor pathogenic ataxin-3 have trouble co-precipitating VCP/p97 (Figure 20B).
Additionally, HRD1 co-precipitated endogenous ataxin-3 from cells (Figure 20C) and
VCP/p97 can co-precipitate endogenous ataxin-3 as well (Figure 20D). Because
ataxin-3 and HRD1 co-immunoprecipitate in transient transfections, and transfected
HRD1 could co-precipitate endogenous ataxin-3, we wanted to use antibodies to HRD1
and ataxin-3 to examine their endogenous co-localization using immunofluorescence
(described in Materials and Methods). Indeed, ataxin-3 and HRD1 co-localize in
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FIGURE 20: ATAXIN-3 INTERACTS WITH HRD1 AND VCP/p97
IN MAMMALIAN CELLS
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FIGURE 20: HEK-293 cells were transiently transfected with the indicated constructs.
48 hours later, FLAG-ataxin-3 or Myc-ataxin-3 was immunoprecipitated using beadbound anti-FLAG or anti-Myc antibody. (A, B) Wild type and pathogenic ataxin-3 coprecipitate HRD1 (A) or VCP/p97 (B). Note that less HRD1 co-precipitates with
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transiently transfected HRD1 or VCP/p97 from HEK-293 cells.
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FIGURE 21: ATAXIN-3 CO-LOCALIZES WITH THE UBIQUITIN LIGASE HRD1
IN MAMMALIAN CELLS
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FIGURE 21: Fluorescent images of HeLa cells transfected with Myc-HRD1 and
stained for the Myc-tag, as well as endogenous ataxin-3. Arrows and sections identify
co-localization of HRD1 and ataxin-3.
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mammalian cells (Figure 21; arrows).
We next investigated if ataxin-3 opposes the ubiquitin ligase activity of HRD1 in
cells. As shown in Figure 22, HRD1 leads to lower steady state levels of a classical
ERAD substrate, CD3δ, as also previously reported [118]. Wild type ataxin-3 opposes
the effect of HRD1 on CD3δ protein levels in a manner that depends on its DUB
catalytic activity. These data suggest that ataxin-3 opposes the targeting for degradation
of ERAD substrates by HRD1. This could be through direct deubiquitination of ERAD
substrates by ataxin-3.
6.2.2 Ataxin-3 reduces polyubiquitin chains formed by HRD1 in vitro
We next examined if ataxin-3 modifies polyubiquitin chains formed by HRD1 in
vitro. To investigate the functional interaction of HRD1 with ataxin-3, wild type ataxin-3
was incubated in the same biochemical reactions as Figures 10-13 (described in
Materials and Methods). In the presence of ataxin-3, the rate of formation of
polyubiquitin chains is dramatically decreased (Figure 23), suggesting that ataxin-3
disassembles ubiquitin chains formed by HRD1. Additionally, the effect of ataxin-3 on
HRD1 chain formation depends on its DUB enzymatic activity (Figure 24). Together,
these data (Figures 20-24) help elucidate the regulatory role for ataxin-3 in HRD1
turnover by suggesting that ataxin-3 functions with HRD1 in ERAD related duties, but
ataxin-3 works to oppose HRD1’s innate ubiquitin ligase function by opposing HRD1dependent substrate turnover in cells and reducing polyubiquitin chains in vitro.
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FIGURE 22: ATAXIN-3 OPPOSES HRD1’S EFFECT ON STEADY STATE LEVELS OF
THE ERAD SUBSTRATE CD3δ
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FIGURE 23: ATAXIN-3 OPPOSES HRD1 ACTIVITY IN VITRO

FIGURE 23: Western blot of in vitro biochemical reactions containing the specified
components (0.3 μM E1 activating enzyme, 1 μM Ube2G2 (E2) and HRD1 (E3), 60
μM ubiquitin, 1 μM ataxin-3, 5 mM MgCl2/ATP). Note the ability of recombinant
ataxin-3 to reduce the levels of ubiquitinated species formed by HRD1 and Ube2G2 in
vitro. Below is a semi-quantification of data.
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FIGURE 24: ATAXIN-3 DUB ACTIVITY IS NECESSARY TO DISASSEMBLE CHAINS
FORMED BY THE LIGASE HRD1

FIGURE 24: Ubiquitination reactions were stopped after 90 minutes with excess
EDTA; 1 μM ataxin-3 was added and fractions were collected as indicated.
Catalytically active ataxin-3 rapidly cleaves ubiquitin chains after they are formed.
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6.3 Ubiquitin-specific 25 (USP25) and ERAD
Similarly to ataxin-3, ubiquitin-specific 25 (USP25) is a catalytically active DUB in
vitro [188, 224]. USP25 has previously been implicated in regulating the proteasomal
turnover of muscle proteins [188]. We wondered if USP25 functions in ERAD with HRD1
and other known components. The work presented in this section was originally
published in PLoS ONE [201], where I was a co-author responsible for conducting
experiments and analyzing corresponding data.
6.3.1 USP25 interacts with ERAD proteins
A previous study reported that the cellular distribution of USP25 (Figure 25A)
mimics ER staining for both the wild type and muscle-specific isoforms [187]. Using
immunofluorescence with an endogenous ER marker (KDEL; ER protein retention
receptor 1), we found that USP25 does indeed co-localize at the ER (Figure 25B; Panel
IC, II, III). We proceeded to use mammalian cells and co-immunoprecipitations to
examine if USP25 physically interacts with known ERAD proteins. We found that
transiently transfected USP25 does co-precipitate the ubiquitin ligase HRD1, as well as
endogenous VCP/p97 (Figure 25C). The opposite experiment confirms that exogenous
HRD1 co-precipitates USP25 and endogenous VCP/p97 protein (Figure 25D).
Furthermore, HRD1 is able to co-precipitate endogenous USP25 in cells (Figure 25E),
but interestingly, USP25 does not seem to physically interact with other E3 ligases
reported to function in ERAD: UFD2/E4B (Figure 25F) and GP78/AMFR (Figure 25G).
Together, these data imply that USP25 is able to selectively interact with at least two
ERAD proteins.
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6.3.2 USP25 regulates the turnover of various ERAD substrates
CD3δ is a classic ERAD substrate [101, 118, 225] and we have shown its turnover
to be dependent on the activity of HRD1 confirming the findings of other reports [118]
(Figure 22). We proceeded to test if USP25 can regulate the steady state levels of
CD3δ in the same way we demonstrated with ataxin-3 (Figure 22). Both isoforms of
USP25 increase steady state protein levels of CD3δ and this DUB seemingly rescues
the substrate from degradation by the proteasome because MG132 treatment
(proteasome inhibition) abolishes the stabilization in CD3δ protein levels (Figure 26A).
Additionally, the catalytic cysteine (C178) and N-terminal ubiquitin-associated and
ubiquitin-interacting domains of USP25 are required to increase steady state levels of
CD3δ because mutating the catalytic residue or deletion of either ubiquitin domain
results in decreased CD3δ protein levels (Figure 26B, 26C). USP25 and CD3δ were
also determined to physically interact via co-immunoprecipitation experiments and
CD3δ can co-precipitate endogenous HRD1 and USP25 suggesting that this ubiquitin
ligase and DUB may each play a role in the regulation of CD3δ (Figure 26D, 26E).
In addition to CD3δ, β-amyloid precursor protein (APP) is an ERAD substrate
regulated by the ubiquitin ligase HRD1 [226]. We wondered whether USP25’s regulatory
role with CD3δ extends to other ERAD substrates. Indeed, exogenous USP25 leads to
increased levels of APP protein in cells, however proteasomal inhibition by the
pharmacological inhibitor MG132 abolishes this steady state increase (Figure 27A). This
suggests that USP25 is important in rescuing APP from enzymatic degradation. Via
cycloheximide pulse-chase experiments, USP25 slows down the turnover of APP
(Figure 27B) suggesting that USP25 over-expression increases APP half-life dependent
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FIGURE 25: USP25 SELECTIVELY CO-PRECIPITATES ERAD PROTEINS
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FIGURE 25: (A) Cartoon representation of known mammalian isoforms of wild type
(WT) or muscle-specific (m) USP25. (B) HEK-293 cells were transfected with the HAUSP25 DNA construct and 48 hours post-transfection, the cells were fixed and
imaged as described in materials and methods. Panels IA, IB, and IC are sections (1
μM) of a cell labeled for ER (KDEL), HA-USP25, and nucleus (DAPI). Panel IC is the
merged image of IA and IB. Panels II and III are merged images of different cells
under the same conditions. Scale bar represents 10 μM. (C-G) HEK-293 cells were
transfected as indicated and immunopurified with bead-bound antibody specific to the
protein tag of interest. Eluates were loaded onto SDS-PAGE for western blotting.
Western blots are representative images of several, independent repeats with similar
results.
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FIGURE 26: USP25 PREVENTS THE DEGRADATION OF CD3δ
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FIGURE 26: (A-C) HEK-293 cells were transfected as described and treated with the
MG132 proteasome inhibitor, or cycloheximide to inhibit protein synthesis as
indicated. Pharmacological treatments were added to cells 48 hours after initial
transfection and cells were subsequently harvested for western blotting. WT: wild type.
USP25(m): muscle-specific isoform. C178S: catalytic cysteine mutated to a serine
residue [188]. ΔUIM: deletion of both UIMs. ΔUBA: deletion of the UBA.
Quantifications represent bands from western blots and other independent
experiments with similar results. CD3δ protein was normalized to loading control.
Shown are means +/- standard deviations. P values were calculated from Student Ttests. (D, E) HEK-293 cells were transfected with the indicated constructs, and 48
hours post-transfection were immunopurified with bead-bound antibody against the
protein tag of interest for 6 hours. Eluates were loading onto SDS-PAGE for western
blotting.
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on the catalytic activity of the DUB because catalytically inactive USP25 does not
effect APP turnover (Figure 27B).
HEK-293 cells express endogenous APP; therefore we wanted to test USP25
rescue without over-expressing the DUB, mimicking more physiological conditions. We
examined steady state APP levels while knocking down USP25 via shRNA transfection
to test whether decreased endogenous protein levels of USP25 decreases
endogenously expressed APP. Despite achieving only modest knockdown in cells, a
decrease in endogenous USP25 protein reduces endogenous APP steady state levels
(Figure 27C). Together with the knowledge that USP25 and APP co-immunoprecipitate
in cells (Figure 27D), these results implicate this DUB in the regulation of APP
degradation.
Although the evidence presented here implicates USP25 in the regulation of ERAD
substrate degradation, we also examined the possibility that this DUB acts on both
ERAD and non-ERAD substrates. Using the ERAD substrate CFTRΔF508 [107] and the
non-ERAD substrates Ub-R-GFP [197] and GFP-ODC [198], we determined that USP25
does affect the steady state levels of CFTRΔF508, but does not impact the non- ERAD
substrates (Figure 27E, 27F). Collectively (Figure 27), these data implicate USP25 more
generally in the regulation of ERAD substrate turnover.
6.3.3 USP25 opposes HRD1’s ligase effect in cells
Because CD3δ physically interacts with both USP25 and HRD1 in cells, we
wanted to examine the functional, combinatorial effect this DUB and ubiquitin ligase has
on CD3δ. HRD1 decreases CD3δ steady state protein levels in a catalytic activitydependent manner (Figure 28A). Similar to what we described with ataxin-3 (Figure 22),
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FIGURE 27: CERTAIN ERAD SUBSTRATES ARE DEGRADED BY USP25

FIGURE 27: (A, B) HEK-293 cells transfected with the indicated DNA constructs, and
where noted were pharmacologically treated with MG132 or cycloheximide before
harvesting 48 hours post-transfection. Histograms represent the quantification of
normalized APP signal from several independent experiments. Shown are means +/standard deviations and P values are calculated via Student T-tests. (C) HEK-293
cells were transfected with shRNA constructs targeting endogenous USP25. Cells
were harvested 48 hours after initial transfection. Semi-quantification of normalized
APP signal are from the western blot shown, and other similar experiments. Asterisk:
P<0.01 calculated by Student T-tests. (D) HEK-293 cells transfected with indicated
constructs and after 48 hours, cells were lysed and immunopurified with bead-bound
antibody to Myc-USP25. (E, F) HEK-293 cells were transfected with the indicated
DNA constructs and lysates were loaded onto SDS-PAGE for western blotting.
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CD3δ degradation in the presence of HRD1 is rescued by exogenous USP25 (Figure
28A), supporting a model where this DUB reverses the ubiquitin ligase function of
HRD1.
To investigate the role(s) of USP25 and HRD1 on CD3δ ubiquitination, we used
stringent immunopurification (described in Materials and Methods) to isolate CD3δ from
HEK-293 cells. As might be expected, exogenous USP25 reduces CD3δ ubiquitination.
Importantly, over-expression of the catalytically inactive USP25 DNA construct does not
noticeably change CD3δ protein levels, or its ubiquitination and degradation rates
(Figure 28B, 28C) suggesting that this DUB may rescue CD3δ from enzymatic
degradation by the proteasome via deubiquitination.
6.3.4 USP25 decreases HRD1- or VCP/p97-associated ubiquitin species
Due to HRD1’s innate role as an E3 ubiquitin ligase, its main responsibility is the
ubiquitination of endogenous proteins in order for proteasomal degradation to occur. In
order to examine if USP25 affects the ubiquitination status of proteins associated with
ERAD components, we immunopurified endogenous proteins associated with HRD1
from cells either over-expressing USP25 or not.
In Figure 29A, USP25 reduces the levels of ubiquitinated species that coimmunoprecipitate with HRD1 in a manner dependent on its catalytic activity, and its
ubiquitin-binding and ubiquitin-interacting motifs. Interestingly, deletion of the ubiquitininteracting or ubiquitin-binding regions on USP25 does not abolish its interaction with
HRD1 (Figure 29B), together (Figure 29A, 29B) suggesting that USP25 opposes HRD1
ligase function in cells by cleaving ubiquitin chains.
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FIGURE 28: USP25 OPPOSES HRD1’S UBIQUITIN LIGASE ACTIVITY ON
CD3δ IN MAMMALIAN CELLS

FIGURE 28: (A) HEK-293 cells were transfected with the indicated DNA constructs,
harvested 48 hours after the initial transfection and whole cell lysates were loaded
onto SDS-PAGE for western blotting. WT: wild type. CA: catalytically inactive.
Histograms represent quantifications from this and other similar experiments. Shown
are means +/- standard deviations where CD3δ is normalized to loading control. P
values are calculated from Student T-tests. (B, C) HEK-293 cells were transfected with
the indicated DNA and treated with the proteasome inhibitor MG132 for 6 hours, 48
hours after transfection. HA-tagged CD3δ was immunopurified under stringent
conditions (Materials and Methods). Histograms show semi-quantification of ubiquitin
smears labeled in brackets from here and other independent results. Means +/standard deviation are shown and P values calculated via Student T-tests.
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FIGURE 29: USP25 DEUBIQUITINATES ENDOGENOUS PROTEINS IN ERAD

FIGURE 29: (A-C) HEK-293 cells were transfected with the DNA constructs as
indicated and after 48 hours, cells were harvested, lysed and immunopurified with
bead-bound antibody specific to the V5 tag (A, B) on HRD1-associated proteins or the
GFP tag (C) on VCP/p97-associated proteins. Histograms are semi-quantifications of
this and other similar experiments showing means +/- standard deviations. P values
for panels (A) and (C) are the result of Student T-tests.
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Lastly, we tested whether USP25 affects the ubiquitination status of ubiquitin
species associated with the proteasomal shuttle protein VCP/p97 (Figure 29C). USP25
reduces the levels of ubiquitin species of proteins associated VCP/p97; however, the
reduction is not as dramatic as we see with HRD1-associated proteins. Altogether,
these data implicate USP25 in ERAD substrate turnover.
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CODA
Protein quality control comprises a set of basic cellular pathways that are
indispensable for all cells, tissues and organs and regulate the turnover of most cellular
proteins. The importance of protein quality control mechanisms is underscored by
cancers, neurological diseases and metabolic syndromes caused by or linked to
aberrations in one of more of its components. A principal pathway in protein quality
control is ER-Associated Degradation (ERAD), which regulates the turnover of proteins
synthesized in the ER by recognizing misfolded, anomalous proteins and ubiquitinating
them for the purposes of proteasomal degradation.
New evidence has documented the involvement of several ERAD components in
malignancies. In my own research, I found that HRD1, an E3 ubiquitin ligase that
functions in ERAD, is expressed differentially by various cancer cell lines in combination
with varying types of E2 ubiquitin-conjugases, suggesting that different ubiquitin chains
are formed in ERAD under varying conditions. HRD1 and its collaborating ubiquitinconjugases are also differentially expressed in various mouse organs. Additionally, the
expression of HRD1 and of the E2 ubiquitin-conjugases with which it functions is
dynamically regulated in response to stress in cell culture. Collectively, these findings
led us to wonder whether HRD1 makes different types of ubiquitin-ubiquitin linkages
with different E2 ubiquitin-conjugases.
"

Through in vitro reconstituted systems, I determined that HRD1 and the ubiquitin-

conjugase Ube2G2 construct only K48-linked polyubiquitin. This type of chain is usually
coupled to protein degradation by the proteasome. However, HRD1 in the presence of
another conjugase, Ube2J1, forms unconventional (K11-, K29-, and K33-linked
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polyubiquitin) chains. The roles of these chains in proteolytic or non-proteolytic
processes are unclear. These results suggested that ERAD substrates are processed
differently under specific conditions. The formation of these polyubiquitin chains was
markedly enhanced by a third conjugase, Ube2W, indicating that the activity and
function of HRD1 can be directly upregulated by the conjugase with which it interacts;
this might hold particularly during ER stress, as gene transcription of Ube2W is
markedly increased during physiological and pharmacological stressors tied to ERAD.
"

The interaction of HRD1 with the proteasomal shuttle protein VCP/p97 may

provide an additional layer of HRD1 control by determining some types of ubiquitin
linkages generated by the ligase, even though this direct interaction between E3
ubiquitin ligase and VCP/p97 is not strictly required for polyubiquitin chain formation.
The role of VCP/p97 in this system is potentially complex: the data presented suggest
that VCP/p97 plays a variety of regulatory roles in ERAD. Generally thought to function
during substrate extraction from the ER and during its degradation, it is possible that
VCP/p97 may have roles during active ubiquitination as well.
The idea that HRD1 forms K48-linked ubiquitin chains in cells is not particularly farfetched. Since ERAD-related ubiquitin ligases tag misfolded, toxic, or short-lived
proteins with ubiquitin, most substrates of ligases are thought to be degraded by the
26S proteasome and K48 ubiquitin linkages have long been associated with enzymatic
degradation by the proteasome. However, our findings that HRD1 can make K63-linked
ubiquitin conjugates in mammalian cells implies that perhaps HRD1 has functions
outside of ERAD, or even that K63-linkages may play a role in substrate degradation in
some way, which to the best of our knowledge has not been reported in peer-reviewed
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journals. My studies implicate the use of specific types of ubiquitin chains under diverse
conditions in ERAD and in different tissues. Importantly, the type of ubiquitination
occurring on HRD1 substrates is dictated not by this protein, but by its binding partners.
This is a novel finding that will alter the way in which we think about degradative
processes.
Based on the data presented here, HRD1 seems to work in concert with at least
two DUBs during ERAD, ataxin-3 and USP25: HRD1 ubiquitinates ERAD substrates
targeting them for degradation by the proteasome, while ataxin-3 or USP25
deubiquitinate them rescuing the protein from degradation. Together, this work
delineates some of the molecular mechanisms of ERAD from the perspective of ligases,
ubiquitin-conjugases and DUBs, providing clues into the regulation of HRD1 activity in
cells.
Understanding how proteins are targeted for degradation allows us to intervene
therapeutically in cancers and other proliferative diseases at the earliest possible step
and with the highest degree of specificity. Collectively, these data explain molecular
mechanisms of degradation and these data will likely aid in the identification of new
targets for therapeutic intervention in the future.
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FUTURE DIRECTIONS
Collectively, this work provides new insights into the functional interaction between
ubiquitin-conjugases (Ube2J1, Ube2G2), a ligase (HRD1) and DUBs (ataxin-3, USP25)
in ERAD. Unless the ERAD process is monitored at various regulatory steps and
through checkpoints, the interaction between its components could prove energetically
wasteful and ultimately destructive. There could be instances when HRD1 function
predominates (ERAD is pushed forward) and others when ataxin-3 or USP25 for
example takes over (ERAD is held back). How this interaction is regulated in cells must
be further investigated.
Regulation of ERAD at the level of substrate ubiquitination or deubiquitination
could occur by controlling the recruitment of DUBs to HRD1 (through direct or indirect
interactions) or through the regulation of HRD1’s activity (e.g. by Ube2W or VCP/p97).
One could investigate this interaction examining HRD1-associated complexes under
normal conditions, or at various points during ERAD. Using both normal and disease
cell lines, together with cycloheximide-based transcriptional holds and releases, one
could isolate HRD1 complexes at various stages of protein synthesis and degradation
related to ERAD and assay them qualitatively and quantitatively through mass
spectrometry-based approaches.
Besides sorting out the ERAD pathway in cells to understand the collaboration
between proteins, aberrant ERAD, as stated earlier, is implicated in a number of human
diseases. Ubiquitin-dependent pathways are intrinsically central to the etiology of many
diseases due to malfunctions in them generally causing an accumulation of toxic
protein, essentially abolishing cellular homeostasis. In cells, it would be of interest to
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determine what other proteins accumulate at the ER during different disease conditions.
By isolating the ER after proteasomal inhibition in cells or by isolating ER in different
tissues from mice, mass spectrometry could also be able to identify protein complexes
that function during stress and disease, compared to normal conditions.
Work in vivo using rodent or other model organisms would be an essential
component to understanding how mutations in pathways such as ERAD contribute to
the formation of cancers or neurodegenerative disease. For a quick read-out of the
proteins important in this system, using Drosophila melanogaster that are expressing
toxic proteins in the fly eyes, RNAi-dependent knockout of HRD1, VCP/p97, and other
ERAD components such as DUBs through morphology, electrophysiology and western
blotting would allow us to investigate degenerative and protective phenotypes in this
model. This would allow us to better understand how the collaboration of these proteins
in vivo contribute to disease, or even protect against it. Phenotypic differences in fly
eyes will provide important molecular clues into the biology of ERAD components in
vivo.
It would also be of interest to further understand the type(s) of polyubiquitin chains
formed by HRD1 or other ubiquitin ligases. Our work shows that HRD1 is able to
generate at least K48- and K63-linked conjugates. There are of course other lysine
residues on ubiquitin that can form chains, each with potentially distinct molecular roles
in ERAD and other basic cell processes. It is possible that polyubiquitin chains not
investigated here contribute to disease pathogenesis or maybe even protection. A better
understanding of the roles of ubiquitin linkages in specific diseases and the proteins that
form these linkages may allow us to better understand how to attack human pathologies
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with small molecules and may greatly accelerate our understanding of diseases caused
by aberrant mechanisms of protein quality control in humans.
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Protein Quality Control (PQC) comprises cellular pathways that regulate the
turnover of short-lived, misfolded proteins. A main component of PQC is Endoplasmic
Reticulum (ER)-Associated Degradation (ERAD), which controls the degradation of
proteins synthesized in the ER. Aberrations in ERAD have been linked to malignancies
such as sarcomas, breast, and pancreatic carcinomas, as well as neurodegenerative
disease. The machinery in this system is complex and while significant progress has
been made to understand ERAD, it is not clear how the different components come
together, or how they are regulated. HRD1 is a resident ubiquitin ligase that has been
proposed as a metastasis suppressor. My goal is to understand how HRD1 is regulated
during normal states and in disease, particularly because my own work suggests
complex mechanisms that regulate this protein and, more generally, ERAD.
"

We found that HRD1, an E3 ubiquitin ligase that functions in ERAD, along with

other PQC components are differentially expressed in various cancer cell lines and in
different mouse tissues, suggesting that specific types of ubiquitin chains are formed in
ERAD under varying conditions. These findings led us to wonder whether HRD1 makes
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different types of ubiquitin-ubiquitin linkages with different E2 ubiquitin-conjugases.
Through in vitro reconstituted systems, we found that HRD1 and the ubiquitin-conjugase
Ube2G2 make only K48-linked polyubiquitin. This type of chain is classically tied to
protein degradation by the proteasome. However HRD1, in the presence of another
conjugase Ube2J1, forms unconventional K11-, K29-, and K33-linked polyubiquitin
chains. These in vitro findings suggested that ERAD substrates are processed
differently under specific conditions. In cells, HRD1 makes at least K48- and K63-linked
polyubiquitin chains with Ube2G2 and Ube2J1, and the direct interaction of HRD1 with
VCP/p97, while not required for polyubiquitin chain formation by this E3 ligase, may
determine some types of ubiquitin chains formed by HRD1 with either E2 conjugase.
Our findings suggest that HRD1 has specific partners in different tissues with potentially
different ERAD outcomes. My work has broad implications in pathophysiology; it may
emphasize specific sites of therapeutic intervention, and will provide significant clues
into the functional balance of protein quality control in normal and disease states.
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